

Vanderbilt University Medical Center

**Consolidated Financial Statements and
Supplementary Information
Years Ended June 30, 2022 and 2021**

Vanderbilt University Medical Center
Index to Consolidated Financial Statements
June 30, 2022 and 2021

	Page
Report of Independent Auditors	1
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7
Report of Independent Auditors on Supplementary Information	46
Consolidating Balance Sheets	47
Consolidating Statements of Operations	49
Note to Supplementary Financial Information	51

Report of Independent Auditors

The Board of Directors
Vanderbilt University Medical Center

Opinion

We have audited the consolidated financial statements of Vanderbilt University Medical Center (VUMC), which comprise the consolidated balance sheets as of June 30, 2022 and 2021, and the related consolidated statements of operations, changes in net assets and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of VUMC at June 30, 2022 and 2021, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of VUMC and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about VUMC’s ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of VUMC's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about VUMC's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Ernst & Young LLP

September 30, 2022

Vanderbilt University Medical Center
Consolidated Balance Sheets
June 30, 2022 and 2021

<i>(\$ in thousands)</i>	2022	2021
Assets		
Current assets:		
Cash and cash equivalents	\$ 651,720	\$ 837,312
Current investments	255,090	215,484
Patient accounts receivable	658,644	553,874
Grants and contracts receivable	88,793	77,365
Inventories	134,557	140,281
Other current assets	122,903	118,259
Total current assets	<u>1,911,707</u>	<u>1,942,575</u>
Restricted cash	18,662	27,404
Noncurrent investments	773,234	779,389
Noncurrent investments limited as to use	150,925	127,414
Property, plant, and equipment, net	1,679,768	1,630,325
Operating lease assets	826,560	839,850
Other noncurrent assets	166,734	96,351
Total assets	<u>\$ 5,527,590</u>	<u>\$ 5,443,308</u>
Liabilities and Net Assets		
Current liabilities:		
Current portion of long-term debt	\$ 18,193	\$ 14,704
Short-term borrowings	—	300,000
Accounts payable and other accrued expenses	404,059	356,171
Medicare accelerated payments	15,956	189,427
Estimated liabilities under third-party programs	89,328	37,669
Accrued compensation and benefits	353,270	316,531
Current portion of operating lease liabilities	68,510	67,343
Current portion of deferred revenue	9,494	4,240
Current portion of medical malpractice self-insurance reserves	15,820	15,820
Total current liabilities	<u>974,630</u>	<u>1,301,905</u>
Long-term debt, net of current portion	1,728,263	1,432,150
Noncurrent portion of operating lease liabilities	783,178	795,330
Fair value of interest rate exchange agreements	45,019	76,864
Noncurrent portion of medical malpractice self-insurance reserves	65,816	56,770
Noncurrent portion of deferred revenue	1,560	2,923
Other noncurrent liabilities	8,856	46,986
Total liabilities	<u>3,607,322</u>	<u>3,712,928</u>
Net assets without donor restrictions:		
Net assets without donor restrictions controlled by Vanderbilt University Medical Center	1,631,068	1,497,483
Net assets without donor restrictions related to noncontrolling interests	20,768	8,339
Total net assets without donor restrictions	<u>1,651,836</u>	<u>1,505,822</u>
Net assets with donor restrictions	268,432	224,558
Total net assets	<u>1,920,268</u>	<u>1,730,380</u>
Total liabilities and net assets	<u>\$ 5,527,590</u>	<u>\$ 5,443,308</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Operations
Years Ended June 30, 2022 and 2021

<i>(\$ in thousands)</i>	2022	2021
Operating revenues		
Patient service revenue	\$ 5,356,273	\$ 4,691,814
Academic and research revenue	705,859	614,611
Other operating revenue	278,736	228,204
Total operating revenues	6,340,868	5,534,629
Operating expenses		
Salaries, wages, and benefits	3,304,333	2,836,544
Supplies and drugs	1,426,939	1,216,203
Facilities and equipment	306,378	296,748
Services and other	919,405	795,287
Depreciation and amortization	172,999	151,454
Interest	59,930	60,530
Total operating expenses	6,189,984	5,356,766
Income from operations	150,884	177,863
Nonoperating revenues and expenses		
(Loss) income from investments	(71,057)	68,201
Gift income	21,477	19,104
Earnings of unconsolidated organizations	9,392	8,100
Unrealized gain on interest rate exchange agreements, net of cash settlements	25,841	17,372
Other nonoperating gains	5,957	—
Total nonoperating revenues and expenses	(8,390)	112,777
Excess of revenues over expenses	142,494	290,640
Excess of revenues over expenses attributable to noncontrolling interests	(8,886)	(6,295)
Excess of revenues over expenses attributable to VUMC	133,608	284,345
Other changes in net assets without donor restrictions		
Change in noncontrolling interests' net assets	12,429	1,704
Net assets released from restriction for capital	6,733	474
Other changes	(6,756)	3,868
Total changes in net assets without donor restrictions	\$ 146,014	\$ 290,391

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Changes in Net Assets
Years Ended June 30, 2022 and 2021

<i>(\$ in thousands)</i>	2022	2021
Net assets without donor restrictions		
Net assets without donor restrictions at the beginning of the period	\$ 1,505,822	\$ 1,215,431
Excess of revenues over expenses	133,608	284,345
Change in noncontrolling interests' net assets	12,429	1,704
Net assets released from restriction for capital	6,733	474
Other changes	(6,756)	3,868
Change in net assets without donor restrictions	146,014	290,391
Net assets without donor restrictions at the end of the period	<u>\$ 1,651,836</u>	<u>\$ 1,505,822</u>
Net assets with donor restrictions		
Net assets with donor restrictions at the beginning of the period	\$ 224,558	\$ 186,555
Contributions	73,294	46,824
Restricted investment (loss) income	(8,482)	11,169
Net assets released from restrictions for operations	(15,697)	(15,647)
Net assets released from restriction for capital	(6,733)	(474)
Other changes	1,492	(3,869)
Change in net assets with donor restrictions	43,874	38,003
Net assets with donor restrictions at the end of the period	<u>\$ 268,432</u>	<u>\$ 224,558</u>
Total net assets		
Beginning of the period	\$ 1,730,380	\$ 1,401,986
Change in total net assets	189,888	328,394
End of the period	<u>\$ 1,920,268</u>	<u>\$ 1,730,380</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Cash Flows
Years Ended June 30, 2022 and 2021

(\$ in thousands)	2022	2021
Cash flows from operating activities		
Change in total net assets	\$ 189,888	\$ 328,394
Adjustments to reconcile change in total net assets to net cash provided by operating activities:		
Depreciation and amortization	172,999	151,454
Gain on acquisition of equity method investment	(14,669)	—
Investment losses (gains)	102,832	(64,917)
Purchases of trading securities	(289,027)	(391,959)
Sales of trading securities	306,081	363,454
Unrealized gain on interest rate exchange agreements	(31,845)	(23,478)
Implementation costs incurred on hosting arrangements	(18,108)	—
Restricted contributions for endowments and property, plant, and equipment	(24,323)	(21,755)
Noncash lease expense	76,325	77,755
Other noncash activities	(2,805)	(3,852)
(Decrease) increase in cash due to changes in:		
Patient accounts receivable	(102,805)	(83,324)
Accounts payable and other accrued expenses	51,693	44,666
Medicare accelerated payments	(174,428)	(33,018)
Other assets and other liabilities, net	(42,617)	(31,344)
Net cash provided by operating activities	199,191	312,076
Cash flows from investing activities		
Purchases of property, plant, and equipment	(213,532)	(236,244)
Acquisition of hospitals	—	(15,600)
Acquisition of equity method investment	—	(36,927)
Acquisition of additional investment interest	(7,660)	—
Purchases of long-term securities	(399,028)	(437,281)
Sales and maturities of long-term securities	221,191	295,673
Proceeds on sale of property, plant, and equipment	—	15
Net cash used in investing activities	(399,029)	(430,364)
Cash flows from financing activities		
Proceeds from issuance of long-term debt	361,666	200,000
Draws on lines of credit	—	100,000
Debt issuance costs	(3,160)	(459)
Repayment of long-term debt and lines of credit	(359,292)	(510,267)
Principal payments under finance lease obligations	(7,333)	(5,766)
Restricted contributions for endowments and property, plant, and equipment	24,323	21,755
Distributions to noncontrolling interests	(10,700)	(4,591)
Net cash provided by (used in) financing activities	5,504	(199,328)
Net change in cash, cash equivalents, and restricted cash	(194,334)	(317,616)
Cash, cash equivalents, and restricted cash		
Beginning of the period	864,716	1,182,332
End of the period	\$ 670,382	\$ 864,716

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

1. Description of Organization

Vanderbilt University Medical Center (“VUMC”) is a Tennessee not-for-profit corporation incorporated in March of 2015 to operate an academic medical center including a comprehensive research, teaching, and patient care health system (the “Medical Center”). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University (the “University” or “VU”), as a part of the University’s administrative structure, with the same governing board, legal, financial, and other shared services. VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University (the “Acquisition”).

VUMC owns and operates three hospitals located on the main campus (“Medical Center Main Campus” or “MCMC”) of the University in Nashville, Tennessee: Vanderbilt University Hospital (“VUH”), Monroe Carell Junior Children’s Hospital at Vanderbilt (“MCJCHV”), and Vanderbilt Psychiatric Hospital (“VPH”). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital (“VSRH”), also located on the main campus of the University, through a joint venture with Encompass Health Corp. in which VUMC holds a 50% interest, including a 1% interest held by Vanderbilt Health Services, LLC, (“VHS”), a VUMC wholly owned subsidiary. Effective August 1, 2019, VUMC acquired from Community Health Systems, Inc. (“CHS”): Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital (“VWCH”). Effective January 1, 2021, VUMC acquired from CHS: Tennova Healthcare – Shelbyville and Tennova Healthcare – Harton, now known as Vanderbilt Bedford Hospital (“VBCH”) and Vanderbilt Tullahoma-Harton Hospital (“VTHH”), respectively. At the same time as the acquisition of VBCH and VTHH, VUMC acquired a noncontrolling ownership interest in CHS’s affiliated Tennova Healthcare – Clarksville (“VMH”). VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH are licensed for 1,664 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration (“MCA”).

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of the Vanderbilt Medical Group (“VMG”), and technical revenues and associated expenses for the operation of VUMC’s hospitals and clinic facilities, including VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH. The Clinical Enterprise also includes VHS.

- VUH is a quaternary care teaching hospital licensed for 726 acute care and specialty beds. VUH, a Level I trauma center, provides advanced patient care and serves as a key site for medical education and clinical research conducted by physician faculty. VUH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center. As of June 30, 2022, VUMC held a temporary license provided under the Board for Licensing Health Care Facilities (“BLHCF”) Policy 82 to license 49 additional beds in response to COVID-19. This licensure increase is comprised of 34 observation beds and 15 double occupancy beds. The beds associated with this temporary license are not included in the above VUH bed count.
- MCJCHV is a pediatric quaternary care teaching hospital licensed for 343 beds (159 acute and specialty, 65 pediatric intensive care, and 119 neonatal intensive care). MCJCHV is the region’s only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level 1 pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

- VPH is a psychiatric hospital licensed for 106 beds and provides inpatient care to pediatric, adolescent, adult, and geriatric patients. Also, VPH provides partial hospitalization programs to both adult and adolescent patients, psychiatric assessment services, adult intensive outpatient programs, pediatric and adult ambulatory outpatient treatment, and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.
- VWCH is a two-campus facility licensed for 245 beds and is a substantial provider of both inpatient and outpatient medical services in Lebanon, Tennessee. Services offered include an accredited chest pain center, a stroke center, and a comprehensive total joint program for orthopedics. In addition, Vanderbilt Ingram Cancer Center extended services to this campus in 2020, and it includes a state-of-the-art linear accelerator.
- VBCH is a 60 licensed bed, Joint Commission-accredited hospital, which offers a range of inpatient and outpatient medical and surgical services, along with urgent care services.
- VTHH is a 135 licensed bed Joint Commission-accredited hospital, which offers a full range of inpatient and outpatient surgical and specialty services including a sleep center, cardiac rehabilitation, and physical rehabilitation. The hospital also features an accredited Chest Pain Center.
- VMG is the practice group of physicians and advanced practice practitioners employed by VUMC, many of whom, when appropriate and required, have faculty appointments from the University, who perform billable professional medical services. VMG is not a separate legal entity. VMG has a board which consists of the VUMC clinical service chiefs, who also serve as clinical department chairs. Under the oversight of VUMC executive leadership, VMG sets professional practice standards, bylaws, policies, and procedures. VUMC bills for services rendered by VMG clinicians in both inpatient and outpatient locations. Collected fees derive a component of each VMG clinician's compensation. VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. VMG members are "board certified" or eligible for board certification, as required by bylaws. All VMG members are re-credentialed every two years in accordance with the Centers for Medicare and Medicaid Services, The Joint Commission, and the National Committee for Quality Assurance Standards. The majority of the specialties and subspecialties currently recognized by the various national specialty boards are represented on the clinical faculty.
- VHS serves as a holding company for 16 first-tier health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH and the Vanderbilt Health Affiliated Network ("VHAN"). VHS operations primarily consist of community physician practices, walk-in and retail health clinics, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, accountable care organizations, and a rehabilitation hospital. These subsidiaries include clinics managed in multiple outpatient locations throughout middle Tennessee and southwestern Kentucky.
- Health Professional Solutions, LLC ("HPS") is a holding company that holds interest in five VUMC subsidiaries that engage in or support various health care related activities in order to improve the quality and availability of health care services in the community. These subsidiaries include businesses focused on pharmacy, supply chain, and clinically integrated support services.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

- Nashville Biosciences, LLC (“NashBio”) operates exclusively in support of VUMC’s non-academic medical research activities. NashBio deploys the biospecimens and genomic data and de-identified medical records of VUMC known as “BioVU”, along with other information, to provide commercial services and products to life science industry customers in connection with pharmaceutical, biotechnology, and medical research and development activities.

The Academic Enterprise division includes all research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC’s research has historically been the federal government. Federal funding is received from the Department of Health and Human Services, the Department of Defense, the National Science Foundation, and other federal agencies. Sponsored research awards, including multi-year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. Also, core activities supporting research, including advanced computing and grant administration, are included in this division.

VUMC has entered into debt agreements further discussed below. Certain of these debt agreements contain required disclosures outlining annual and quarterly reporting requirements. In addition, certain of these debt agreements require notices of the occurrence of significant events which include but are not limited to delinquencies, bond calls, rating changes, bankruptcies, and mergers or acquisitions. The Obligated Group includes the wholly-owned hospitals located on the MCMC along with all associated on-campus and off-campus ambulatory clinics, the Academic Enterprise, MCA, VWCH, and VMG.

The terms “Company,” “VUMC,” “we,” “our,” or “us” as used herein and unless otherwise stated or indicated by context refer to Vanderbilt University Medical Center and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by VUMC and its affiliates, and the term “employees” refers to employees of VUMC and its affiliates.

VUMC operates on a fiscal year which ends on June 30. The term “Fiscal” preceding a year refers to a particular VUMC fiscal year.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Based on the existence or absence of donor-imposed restrictions, VUMC classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

Principles of Consolidation

The consolidated financial statements include the accounts of VUMC and its wholly owned, majority-owned, and controlled organizations. Noncontrolling interests in less-than-wholly owned consolidated subsidiaries of VUMC are presented as a component of net assets to distinguish between the interests of VUMC and the interests of the noncontrolling owners. All material intercompany transactions and account balances among the various entities have been eliminated.

VUMC uses the equity method to account for its interests in unconsolidated partnerships, joint ventures, and limited liability entities over which it exercises significant influence. Investment carrying amounts are adjusted for VUMC’s share of investee earnings or losses based on percentage of ownership. Distributions received from unconsolidated entities that represent returns on VUMC’s

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

investment (i.e., dividends) are reported as cash flows from operating activities in VUMC's consolidated statements of cash flows.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. These estimates affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results ultimately could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and maturities of three months or less when purchased. VUMC invests operating assets in a diversified manner. At times, VUMC may have cash and cash equivalents at a financial institution in excess of federally insured limits, and therefore, bears a risk of loss.

Liquidity and Availability

As of June 30, 2022, VUMC has \$2,338.6 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$651.7 million, patient accounts receivable of \$658.6 million, and unrestricted investments of \$1,028.3 million. As of June 30, 2021, VUMC had \$2,386.1 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$837.3 million, patient accounts receivable of \$553.9 million, and unrestricted investments of \$994.9 million. None of these financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditures within one year of the balance sheet date.

VUMC has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, as part of its liquidity management, VUMC invests cash in excess of daily requirements in various short-term investments, including certificates of deposit and short-term treasury instruments.

As more fully described in Note 11 Long-Term Debt, VUMC also has committed lines of credit in the amount of \$150.0 million, which it could draw upon in the event of an unanticipated liquidity need, with no amount drawn as of June 30, 2022 and \$100.0 million drawn as of June 30, 2021.

Revenue Recognition – Patient Services

VUMC contracts with patients to provide healthcare services that are tailored to each patient's medical needs and health conditions. VUMC recognizes patient service revenue over time as performance obligations are ultimately satisfied. Performance obligations related to inpatient services are generally satisfied as the healthcare services are rendered to the patient, which generally begins at the time of patient admission and extends through the time of patient discharge. Performance obligations for outpatient services are generally satisfied on the same day that services are rendered to the patient. VUMC uses a portfolio approach consisting of major payor classes to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. Based on historical collection trends and other analysis, VUMC believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Patient service revenue is recognized on an accrual basis using a best estimate of the transaction price for the type of service rendered to the patient. The transaction price ultimately represents the estimated amount to be received from the patient and third-party payors in exchange for the services rendered by VUMC. VUMC estimates the transaction price based on standard charges, reduced for estimated price concessions. The price concessions include items that are explicit, such as contractual adjustments provided to third-party payors and discounts provided to uninsured and underinsured patients in accordance with VUMC policy, and also implicit in nature, such as the estimated uncollectible amounts from uninsured or underinsured patients. VUMC regularly reviews transactional data for the major revenue categories to evaluate the reasonableness of the transaction price, including any price concessions, and takes into consideration recent experience by payor category and payor agreement rate changes among other factors.

VUMC carries the value of the related patient accounts receivable balances at the transaction price, inclusive of all estimated price concessions. Given the complexities involved in determining amounts ultimately due to VUMC under reimbursement arrangements with third-party payors, which are often subject to interpretation, VUMC may receive reimbursement for healthcare services authorized and provided that differs from these estimates. If actual results differ from these estimates, a change in estimate will be recorded in the period the change is identified and such differences could be material.

VUMC has elected to apply the optional exemption provided in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606-10-50-14 as substantially all of its performance obligations relate to contracts with a duration of less than one year. Therefore, VUMC is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. Unsatisfied or partially satisfied performance obligations are primarily related to in-house patients at the end of the reporting period. The performance obligations for these contracts are generally completed when the patient is discharged, which is typically within a week.

In addition to reimbursement received in fee-for-service arrangements, VUMC participates in certain federal healthcare programs, as well as state and commercial payor programs, through which VUMC may be entitled to additional payments. These arrangements are complex and may extend over multiple accounting periods. The arrangements are subject to the interpretation of federal and state-specific reimbursement rules, new or changing legislation, and final cost report settlements. Any changes to reimbursement rules or the introduction of new or changing legislation could impact levels and timing of reimbursements received from these programs. As a participant in these programs, VUMC is also required to meet certain financial reporting requirements which include the filing of an annual cost report for each hospital. Each annual cost report is also subjected to an audit performed by the regulatory agency and may extend several years before ultimate settlement becomes known. Therefore, determining the actual amounts earned under these programs involves judgement and estimates that may extend into future periods. These estimates are frequently evaluated and subsequently may be adjusted based on new developments or the receipt of new information related to these settlements. If actual results vary from these estimates, a change in estimate will be recorded in the period the change is identified and such differences could be material.

VUMC provides care to patients who meet the criteria for charity care under its financial assistance policy for no payment or at payment amounts less than its established charge rates. VUMC does not recognize the charges that qualify as charity care as revenue because VUMC does not pursue collection of these amounts.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Revenue Recognition – Non-Patient Services

Revenue for non-patient services is recognized at an amount that reflects the consideration VUMC expects to be entitled in exchange for providing goods or services. The amounts recognized reflect considerations due from customers, the U.S. government, and others, and is recognized as performance obligations are satisfied. Primary categories of non-patient revenue include academic and research revenue as well as other miscellaneous activities as further described in Note 8 Other Relevant Financial Information.

VUMC receives funding through grants and contracts issued by departments and agencies of the U.S. government, industry, and other foundation sponsors who restrict the use of such funds to academic and research purposes. VUMC recognizes revenue from these grants and contracts in accordance with contract terms, as defined in the agreements governing that funding. VUMC recognizes facilities and administrative ("F&A") costs recovery as revenue when the allowable expenditure is incurred on the associated grant or contract. This activity represents reimbursement, primarily from the federal government, of F&A costs on sponsored activities.

Grants and contracts receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor and are recorded at the amount that reflects the consideration VUMC expects to receive.

Deferred Revenue

Deferred revenue is recorded for funds received in advance. The related revenue is recognized when the performance obligations have been met.

Gift Income and Pledges

VUMC recognizes unconditional promises to give cash and other assets, referred to as pledges, as gift income at fair value when the pledge is received. Conditional promises to give are recognized as pledges once the conditions are substantially met. Pledges are recognized as net assets with donor restrictions. Gifts received with donor stipulations limiting the use of the donated assets are reported as net assets with donor restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as gift income in the consolidated statements of operations. Gift income is recognized when a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished. Gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions until the assets are placed in service, at which point they are reclassified to net assets without donor restrictions.

Pledges receivable are reported net of allowances for uncollectible amounts based on an analysis of past collection experience and other judgmental factors. Pledges receivable are included in other current or other noncurrent assets in the consolidated balance sheets based on the expected timing of cash flows. VUMC discounts the noncurrent portion of pledges receivables at a rate commensurate with the scheduled timing of receipt. VUMC applied annual discount rates ranging from 0.5% to 1.5% to amounts outstanding as of June 30, 2022 and 2021.

Concentrations of Risk

VUMC grants unsecured credit to its patients, primarily residing in Nashville, Tennessee and the surrounding areas of middle Tennessee, most of whom are insured under commercial, Medicare (both traditional fee-for-service and Managed Medicare), or TennCare agreements. Medicare, Blue Cross Blue Shield ("BCBS"), and TennCare (which includes BCBS of Tennessee, United, and Amerigroup) represent VUMC's significant concentrations of credit risk from payors.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

The collection of revenue and accounts receivables from Medicare, TennCare, Blue Cross, other third-party payors, and patients is a significant source of operating cash flow. The payor composition of patient service revenue and related accounts receivable portfolio may fluctuate from time to time and generally correlate to the prevailing economic conditions, such as periods of economic expansion or recession or changes in unemployment levels, and those fluctuations may impact the realization of patient service revenue and collectability of accounts receivable. Other factors such as unexpected disruptions to business office operations or trends in federal or state governmental and private employer healthcare coverage could affect the ultimate collectability of accounts receivable balances. As a result, VUMC may be exposed to gains or losses in future periods that could affect the financial position and operating cash flows of the organization and may be material to its financial position, operating income and cash flow from operations.

Inventories

VUMC reports inventories at the lower of cost or market, with cost being determined on the first-in, first-out method. Inventories consist primarily of medical supplies, surgical implants, and pharmaceuticals.

Restricted Cash

VUMC reports cash whose use is restricted at cost, which approximates fair value. The cash is primarily restricted for use in purchasing and constructing property, plant, and equipment and restricted cash associated with our self-insurance trust.

Investments

VUMC reports investments held at fair value in the consolidated balance sheets. Private equity investments, multi-strategy hedge funds, and hedged equity funds are reported based on net asset value ("NAV"), provided by the respective fund manager, as a practical expedient to estimate fair value. VUMC records purchases and sales of securities on the trade dates, and realized gains and losses are determined based on the average historical cost of the securities sold. VUMC reports net receivables and payables arising from unsettled trades as a component of investments.

Property, Plant, and Equipment, Net

VUMC records purchases of property, plant, and equipment at cost and expenses repairs and maintenance costs as incurred. VUMC capitalizes interest cost incurred on borrowed funds during the period of construction of capital assets as a component of the cost of acquiring those assets. VUMC capitalizes donated assets at fair value on the date of donation.

Capitalized software for internal use is recorded during the application development stage. These costs include fees paid to third parties for direct costs of materials and services consumed in developing or obtaining the software; payroll related costs and capitalized interest costs. Costs for training and application maintenance in the post-implementation operation stage are expensed as incurred.

VUMC computes depreciation using the straight-line method over the estimated useful life of land improvements (5 to 18 years), buildings and leasehold improvements (2 to 40 years), and equipment (2 to 20 years). Equipment costs also include capitalized internal use software costs, which are expensed over the expected useful life, which is generally 3 to 12 years.

Software for internal use is amortized on a straight-line basis over its estimated useful life. In determining the estimated useful life, management considers the effects of obsolescence, technology, competition, other economic factors, and rapid changes that may be occurring in the development of software products, operating systems, and computer hardware. Amortization begins once the software is ready for its intended use.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Costs Associated with Hosting Arrangements under Service Contracts

Costs associated with hosting arrangements under service contracts are presented in other noncurrent assets on our consolidated balance sheets. These assets total \$18.1 million and \$0 as of June 30, 2022 and June 30, 2021, respectively. The related capitalization policy is consistent with the policy described above for internal use software. Once placed into service, these assets will be amortized over their respective estimated useful lives. Currently these assets largely consist of costs associated with the implementation of an enterprise resource planning system, which has not yet been placed into service.

Impairment of Long-Lived Assets

VUMC reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. VUMC measures the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, VUMC recognizes an impairment charge to the extent the carrying amount of the asset exceeds its fair value.

Conditional Asset Retirement Costs and Obligations

VUMC recognizes the estimated fair value of liabilities for existing legal obligations to perform certain activities, primarily asbestos removal, in connection with the retirement, disposal, or abandonment of assets. These liabilities are included in other noncurrent liabilities on the consolidated balance sheets and total \$7.0 million and \$6.7 million as of June 30, 2022 and 2021, respectively. VUMC measures these liabilities using estimated cash flows with an inflation rate applied of 3.0% as of June 30, 2022 and 2021. VUMC discounts those cash flow estimates at a credit-adjusted, risk-free rate, which ranged from 2.9% to 4.2% as of June 30, 2022 and 2021, and adjusts these liabilities for accretion costs and revisions in estimated cash flows.

Long-Term Debt

The carrying value of VUMC's debt is the par amount adjusted for the net unamortized amount of debt issuance costs and bond premiums and discounts.

Interest Rate Exchange Agreements

VUMC reports interest rate exchange agreements at fair value, which is determined to be the present value of future net cash settlements that reflect market yields as of the measurement date and estimated amounts that VUMC would pay, or receive, to terminate the contracts as of the report date. VUMC considers current interest rates and creditworthiness of the interest rate exchange counterparties when estimating termination settlements.

Self-Insurance Reserves

VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability coverage via an irrevocable self-insurance trust. For Fiscal 2022 and 2021, the maximum annual self-insurance retention was \$6.0 million per occurrence, up to \$46.0 million in the aggregate. Actuarial firms assist management in estimating expected losses on an annual basis, at which time VUMC records medical malpractice, professional, and general liability expense within the limits of the program. These liabilities are classified as current or noncurrent based on the expected timing of cash flows and are measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2022 and 2021. For both Fiscal 2022 and 2021, VUMC obtained excess medical malpractice, professional, and general liability coverage from commercial insurance carriers for claims exceeding the retention limits, up to \$175.0 million. These policies would also provide coverage up to \$175.0 million if any claims in the aggregate exceeded the retention limits.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

VUMC also elects to self-insure for employee health and workers' compensation expenses. Actuarial firms assist management in estimating expected losses on an annual basis. The maximum retention for workers' compensation was \$0.8 million per occurrence for both Fiscal 2022 and 2021. There is no stop loss insurance on health plan claims.

Income Taxes

VUMC is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the "Code") and is generally exempt from federal income taxes under Section 501(a) of the Code.

Excess of Revenues Over Expenses

The consolidated statements of operations include excess of revenues over expenses as a performance indicator. Excess of revenues over expenses includes all changes in net assets without donor restrictions, except for changes in noncontrolling interest holders' share of consolidated entities, net assets released from restrictions used for capital, and certain other items.

Statement of Cash Flows

For VUMC's consolidated statements of cash flows, cash, cash equivalents, and restricted cash is defined as those amounts included in the cash and cash equivalents caption and restricted cash caption on the consolidated balance sheets.

Reclassifications

Certain reclassifications have been made to the Fiscal 2021 consolidated financial statements to conform to the Fiscal 2022 presentation. The reclassifications had no effect on net assets or changes in net assets as previously reported.

Recent Accounting Pronouncements

Periodically, the FASB issues Accounting Standards Updates ("ASUs") that may impact the recognition, measurement, and presentation of balances and activity in VUMC's consolidated financial statements or the disclosures contained within those statements. As part of preparing consolidated financial statements, VUMC evaluates the effects of the ASUs and applies the updated guidance within the required effective dates.

Adopted

- Effective July 1, 2021, VUMC adopted FASB ASU 2018-15, Intangibles – Goodwill and Other, Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. The primary effect of adopting this ASU is the capitalization of implementation costs incurred in hosting arrangements that are service contracts and subsequent amortization expenses in the consolidated statements of operations. The ASU was adopted prospectively and resulted in \$18.1 million of implementation costs being capitalized during Fiscal 2022, which are recorded in other noncurrent assets on the consolidated balance sheet.
- Effective July 1, 2021, VUMC adopted FASB ASU 2020-07, Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets (Topic 958). This ASU requires presentation of nonfinancial assets as a separate line in the consolidated statement of operations, apart from contributions of cash or other financial assets. The adoption of this ASU did not materially impact the consolidated financial statements.
- Effective July 1, 2021, VUMC adopted FASB ASU 2021-03, Intangibles – Goodwill and Other (Topic 350): Accounting Alternative for Evaluating Triggering Events. This ASU provides private companies and not-for-profit entities with an accounting alternative to perform the goodwill

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

impairment triggering event evaluation as required in Subtopic 350-20 as of the end of the reporting period. An entity that elects this alternative is not required to monitor for goodwill impairment triggering events during the reporting period but, instead, should evaluate the facts and circumstances as of the end of each reporting period to determine whether a triggering event exists and, if so, whether it is more likely than not that goodwill is impaired. VUMC has elected this alternative and evaluates goodwill, recorded in other noncurrent assets on the consolidated balance sheet, for impairment as of the end of each annual reporting period. The adoption of this ASU did not have a material impact on our consolidated financial statements.

3. Related Parties

On April 29, 2016, VUMC acquired the assets, liabilities, rights, and obligations of the clinical enterprise, postgraduate medical training programs, and clinically related research of the University's owned and operated Medical Center through the Acquisition.

The assets acquired and liabilities assumed from the Acquisition were detailed in a Master Transfer and Separation Agreement ("MTSA"). The MTSA contains the framework for the ongoing economic relationship between VUMC and the University. The relationship is memorialized in the form of an Academic Affiliation Agreement ("AAA"), a Trademark License Agreement ("TMLA"), a Ground Lease, and a Reciprocal Master Services Agreement ("MSA"). The agreements are described below.

- The AAA outlines the ongoing academic, research, and clinical affiliation between the University and VUMC for all the University's degree-granting, certificate, and research programs. The AAA allocates responsibility between the University and VUMC for jointly administered research and academic programs and is an exclusive agreement between VUMC and VU requiring VUMC to be organized, governed, and operated in a manner that supports VU's academic and research mission. The agreement provides that VU will be the exclusive academic affiliate of VUMC, and VUMC will be the exclusive clinical affiliate of VU.

The AAA requires VUMC to pay VU an annual fee in equal monthly payments adjusted annually for inflation based upon the Biomedical Research and Development Price Index ("BRDPI") in perpetuity under certain mutually agreed-upon termination or default clauses. During Fiscal 2022 and 2021, VUMC recorded operating expense totaling \$79.8 million and \$78.5 million, respectively, in connection with fees due under the AAA.

- Under the TMLA, VU grants, subject to certain consents and approvals, a perpetual license to use various VU-owned licensed marks in connection with VUMC's fundamental activities after the Acquisition date. The licensed marks, which VUMC continues to use as its primary brands, include virtually all those previously in use by VUMC. This agreement requires VUMC to pay VU royalties consisting of a monthly payment equal to 1% of all operating revenue of VUMC and 15% of income from operations. During Fiscal 2022 and 2021, VUMC recorded operating expense totaling \$88.0 million and \$83.7 million, respectively, in connection with the 1% of operating revenue and 15% of operating income payments due under the TMLA. Also, VUMC is required to pay in equal monthly installments an annual TMLA base fee royalty, which increases 3% annually, but is also reduced by the amount of principal payments made under a subordinated note discussed in Note 11 Long-Term Debt (the "Fixed TMLA Royalty Payment"). During Fiscal 2022 and 2021, VUMC recorded operating expense totaling \$66.6 million and \$64.6 million, respectively, in connection with this base fee royalty. In Fiscal 2018, VU sold its rights to future base fee royalty payments to a third party. In Fiscal 2019, VU sold its rights to future 1% of operating revenue payments to a third party. The TMLA is in force in perpetuity under certain mutually agreed-upon termination or default clauses.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

- The Ground Lease is an agreement between VU and VUMC that allows VUMC to use the land on which VUMC's campus and related buildings are located. The initial term of the Ground Lease ends June 30, 2114, with the option to extend the lease for two additional terms of up to 50 to 99 years each with agreement between VU and VUMC. The lease covers 1.7 million square feet or 38.75 acres of space, payable monthly and CPI adjusted annually. During Fiscal 2022 and 2021, VUMC recorded operating expense totaling \$20.4 million and \$19.6 million, respectively, in connection with fees due under the Ground Lease.
- The University and VUMC provide services to one another for agreed-upon consideration as outlined in the MSA. VU provides services to VUMC, such as information technology infrastructure support, utilities, and law enforcement staffing. VUMC provides various operational services for the University, such as a student health clinic and animal care. Additionally, the MSA encompasses an Employee Matters Agreement ("EMA") and specific Employee Service Agreements ("ESAs"). The EMA and ESAs govern employee transactions and ongoing sharing between VU and VUMC in various capacities, such as research, teaching, clinical, and other administrative services. Services under the MSA can be terminated by either party subject to predetermined cancellation notification periods. In connection with the MSA, during Fiscal 2022 and 2021, VUMC recognized revenue totaling \$44.5 million and \$43.4 million, respectively, and recorded operating expense totaling \$121.2 million and \$119.5 million, respectively.
- Also, as part of the Acquisition, VUMC issued to VU a \$100.0 million subordinated promissory note payable, which is further described in Note 11 Long-Term Debt, with a balance of \$69.6 million as of June 30, 2022, and \$74.6 million as of June 30, 2021. VU sold its rights to future principal and interest payments on this note to a third party.

The impact of these agreements in the consolidated statements of operations during Fiscal 2022 and 2021 is as follows:

<i>(\$ in thousands)</i>	2022	2021
Academic and research revenue	\$ 13,540	\$ 15,816
Other operating revenue	30,958	27,565
Total operating revenues	<u>\$ 44,498</u>	<u>\$ 43,381</u>
Operating expenses		
Salaries, wages, and benefits	\$ 9,111	\$ 8,223
Facilities and equipment	58,610	56,910
Services and other	308,290	300,656
Interest	2,336	2,498
Total operating expenses	<u>\$ 378,347</u>	<u>\$ 368,287</u>

Other current assets include amounts receivable from VU, which totaled \$7.0 million as of June 30, 2022, and \$8.0 million as of June 30, 2021. Accounts payable and other accrued expenses include amounts payable to related parties, which totaled \$58.5 million as of June 30, 2022 and 2021.

In the normal course of business, members of VUMC's Board of Directors or VUMC employees may be directly or indirectly associated with companies engaged in business activities with VUMC. VUMC has a written conflict of interest policy that requires, among other things, that members of the VUMC community (including trustees) may not review, approve, or administratively control contracts or business relationships when (i) the contract or business relationship is between VUMC and a

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

business in which the individual or a family member has a material financial interest, or (ii) the individual or a family member is an employee of the business and is directly involved with activities pertaining to VUMC.

Furthermore, VUMC's conflict of interest policy extends beyond the foregoing business activities in that disclosure is required for any situation in which an applicable individual's financial, professional, or other personal activities may directly or indirectly affect, or have the appearance of affecting, an individual's professional judgment in exercising any VUMC duty or responsibility, including the conduct or reporting of research.

The policy extends to all individual members of the VUMC community (including Board of Directors, VUMC officials, full-time, part-time, temporary faculty and staff). Each applicable person is required to certify compliance with the conflict of interest policy on an annual basis. This certification includes specifically disclosing whether VUMC conducts business with an entity in which he or she (or an immediate family member) has a material financial interest, as well as any other situation that could appear to present a conflict with VUMC's best interests.

When situations exist relative to the conflict of interest policy, VUMC takes active measures to appropriately manage the actual or perceived conflict in the best interests of VUMC, including periodic reporting of measures taken to the Audit and Compliance Committee of the Board of Directors.

4. Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements

The sources of patient service revenue by payor for Fiscal 2022 and 2021 are as follows:

<i>(\$ in thousands)</i>	2022	2021
Other third-party payors, primarily commercial carriers	\$ 3,307,671	\$ 2,961,480
Medicare/Managed Medicare	1,262,330	1,084,216
TennCare/Medicaid	724,030	608,791
Uninsured (self-pay)	62,242	37,327
	<u>\$ 5,356,273</u>	<u>\$ 4,691,814</u>

Patient accounts receivable comprise amounts due from the following sources as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Medicare/Managed Medicare	\$ 119,626	\$ 95,382
TennCare/Medicaid	87,357	70,487
Blue Cross	134,528	115,028
Other third-party payors, primarily commercial carriers	260,034	219,643
Patient responsibility ⁽¹⁾	57,099	53,334
Patient accounts receivable	<u>\$ 658,644</u>	<u>\$ 553,874</u>

⁽¹⁾ Includes self-pay after insurance.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Estimated third-party settlements by major payor category as of June 30, 2022 and 2021 are as follows:

<i>(\$ in thousands)</i>	<u>2022</u>	<u>2021</u>
Receivables under third-party programs		
Tricare/Champus ⁽¹⁾	\$ 5,338	\$ 4,635
Total receivables under third-party programs	<u>\$ 5,338</u>	<u>\$ 4,635</u>
Liabilities under third-party programs		
TennCare/Medicaid	\$ 88,296	\$ 33,781
Medicare ⁽¹⁾	6,370	8,170
Other	—	353
Total liabilities under third-party programs	<u>\$ 94,666</u>	<u>\$ 42,304</u>

⁽¹⁾ These two federal healthcare programs are combined for presentation purposes on the face of the consolidated balance sheets and are reflected as an obligation in Fiscal 2022 and 2021.

Certain contracts require pay for performance or episode of care settlements whereby VUMC receives additional payment or pays a penalty based on its ability to achieve certain clinical measures or manage the cost of care for patients within various thresholds. VUMC estimates and accrues these adjustments in the period the related services are rendered and adjusts these estimates in future periods as settlements are finalized. The aggregate liability associated with pay for performance and episode of care settlements at June 30, 2022 and 2021 was \$4.8 million and \$1.1 million, respectively, with the ultimate resolution of such financial arrangements not expected to have a material impact on the operating results of VUMC.

Medicare

Amounts received under Medicare are subject to review and final determination by program intermediaries or their agents. Final settlements have been reached for program periods ended June 30, 2015. Final settlements have not been reached for subsequent years due to audit delays experienced with the Medicare Administrative Contractor, and thus, those periods remain subject to audit by program representatives.

TennCare

TennCare is a Medicaid managed care program implemented by the state of Tennessee to provide healthcare coverage to those patients eligible for Medicaid through the Federal 1115 Waiver Program. VUMC contracts with each of the three TennCare managed care organizations (“MCOs”), which offer health maintenance organization (“HMO”) and Medicare Special Needs Products for Dual Eligible Enrollees. VUMC receives inpatient reimbursement through payments that are primarily based on the Medicare severity diagnostic related group system (“MS-DRG”) for these plans. VUMC receives outpatient payments generally based on an ambulatory payment classification system (“APC”), and/or a payor-developed fee schedule.

In accordance with the Tennessee Hospital Assessment Act, VUMC receives a payment of a portion of its unreimbursed TennCare costs based upon VUMC’s share of uninsured TennCare costs for all of the covered hospitals.

There is no assurance that this program will be continued in its current structure or will not be materially modified in the future, however, we anticipate funding will remain relatively stable over the coming year.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

In Fiscal 2022 and 2021, patient service revenue includes the following supplemental amounts received in each respective period from TennCare.

<i>(\$ in thousands)</i>	<u>2022</u>	<u>2021</u>
Directed payments	\$ 36,633	\$ —
Charity pool	26,026	26,659
Graduate medical education	14,688	14,618
Trauma fund	1,192	1,560
Workforce development and other	2,621	—
Virtual disproportionate share	7,651	6,400
Changes in prior year virtual disproportionate share reserve estimate	—	20,411
Total supplemental TennCare revenue	<u>\$ 88,811</u>	<u>\$ 69,648</u>

5. Charity Care Assistance, Community Benefits, and Other Unrecovered Costs

VUMC maintains a policy which sets forth the criteria under which health care services are provided to patients who have minimal financial resources to pay for medical care. Additionally, VUMC provides other services that benefit the economically disadvantaged for which little or no payment is expected.

Charity care is determined by examining patient and family income relative to the federal poverty guidelines. VUMC provides additional discounts based on the income level of the patient household using a sliding scale for those patients with a major catastrophic medical event not qualifying for full charity assistance. Tennessee law mandates that all uninsured patients receive a discount from billed charges for medically necessary services. These amounts are classified as charity care if the patient meets charity care criteria, for which no revenue is recorded, or are included as a part of price concessions.

VUMC maintains records to identify and monitor the level of charity care provided, and these records include gross charges and patient deductibles, coinsurance and copayments foregone for services furnished under its charity care policy, and the estimated cost of those services. VUMC calculates a ratio of total costs to gross charges and then multiplies the ratio by foregone charity care charges in determining the estimated cost of charity care. The gross amount of foregone charity care revenue in Fiscal 2022 and 2021 totals \$530.5 million and \$474.1 million, respectively. The estimated cost of providing care to charity patients in Fiscal 2022 and 2021 totals \$140.0 million and \$123.6 million, respectively.

In addition to the charity care services described above, TennCare/Medicaid and state indigent programs do not cover the full cost of providing care to beneficiaries of those programs. As a result, in addition to direct charity care costs, VUMC provided services related to TennCare/Medicaid and state indigent programs and was reimbursed substantially below the cost of rendering such services. VUMC also provides public health education and training for new health professionals and provides, without charge, services to the community at large for many patients with special needs.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

6. Academic and Research Revenue, and Grants and Contracts Receivable

Academic and research revenue comprises the following for Fiscal 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Grants and contracts revenue		
Federally funded	\$ 415,566	\$ 345,745
Non-federally funded	123,825	124,690
	539,391	470,435
Facilities and administrative costs recovery	166,468	144,176
Academic and research revenue	<u>\$ 705,859</u>	<u>\$ 614,611</u>

Grants and contracts receivable comprise the following as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Federally funded	\$ 47,210	\$ 38,472
Non-federally funded	41,583	38,893
Total grants and contracts receivable	<u>\$ 88,793</u>	<u>\$ 77,365</u>

7. Pledges Receivable, Net

Pledges receivable, net of applied discounts and allowance for uncollectible pledges, as of June 30, 2022 and 2021, were as follows:

<i>(\$ in thousands)</i>	2022	2021
Amounts due		
Within one year	\$ 19,476	\$ 10,660
In one to five years	34,312	26,257
Total pledges receivable	53,788	36,917
Unamortized discount	(1,336)	(1,225)
	52,452	35,692
Allowance for uncollectible pledges	(6,993)	(4,806)
Net pledges receivable	<u>\$ 45,459</u>	<u>\$ 30,886</u>
Net pledges receivable classified as		
Current	\$ 13,349	\$ 6,615
Noncurrent	32,110	24,271
	<u>\$ 45,459</u>	<u>\$ 30,886</u>

In addition to pledges reported as pledges receivable, VUMC had cumulative bequest intentions and conditional promises to give totaling \$76.6 million and \$79.5 million as of June 30, 2022 and 2021, respectively. Due to their conditional nature, VUMC does not recognize intentions to give as assets. Pledges receivables are presented in other current assets and other noncurrent assets on our consolidated balance sheets, as shown in Note 8.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

8. Other Relevant Financial Information

Other current assets comprise the following as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Prepaid expenses	\$ 35,547	\$ 44,552
Other receivables	61,043	55,295
Amounts due from VU (see Note 3 Related Parties)	7,017	7,977
Current pledges receivable, net (see Note 7 Pledges Receivable, Net)	13,349	6,615
Expected recoveries from commercial insurance excess coverage	5,947	3,820
Total other current assets	<u>\$ 122,903</u>	<u>\$ 118,259</u>

Other noncurrent assets comprise the following as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Equity in unconsolidated organizations	\$ 62,080	\$ 63,109
Noncurrent pledges receivable, net (see Note 7 Pledges Receivable, Net)	32,110	24,271
Goodwill	27,028	—
Implementation costs incurred on hosting arrangements	18,108	—
Other	27,408	8,971
Total other noncurrent assets	<u>\$ 166,734</u>	<u>\$ 96,351</u>

Other operating revenues comprise the following for Fiscal 2022 and 2021

<i>(\$ in thousands)</i>	2022	2021
CARES funding	\$ 72,682	\$ 63,045
Clinical contracts	55,645	49,701
Amounts recognized under MSA with VU (see Note 3 Related Parties)	30,958	27,565
VHS other revenue	22,726	21,556
Nonclinical contracts	20,588	16,846
Resident and house staff rotations	9,123	10,151
Royalty revenue	17,612	1,222
Other	49,402	38,118
Total other operating revenue	<u>\$ 278,736</u>	<u>\$ 228,204</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

9. Investments

VUMC investments are made up of current investments, restricted cash, noncurrent investments, and noncurrent investments limited as to use on the face of the consolidated balance sheets. VUMC investments include assets limited as to use related to the following specified purposes as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Self-insured malpractice program	\$ 49,290	\$ 46,991
Donor endowments	85,430	65,083
Split-interest trusts	8,515	9,503
Supplemental employee retirement program assets	7,690	5,837
	<u>\$ 150,925</u>	<u>\$ 127,414</u>

VUMC's endowment does not include gift annuities, interests in trusts held by others, contributions pending donor designation, or contributions receivable.

The Board of Directors' interpretation of its fiduciary responsibilities for donor-restricted endowments under the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") requirements is to preserve intergenerational equity, barring the existence of any donor-specific provisions. Under this broad guideline, future endowment beneficiaries should receive at least the same level of real economic support as the current generation. The overarching objective is to preserve and enhance the real (inflation-adjusted) purchasing power of the endowment in perpetuity. VUMC invests assets to provide a relatively predictable and stable stream of earnings to meet spending needs and attain long-term return objectives without the assumption of undue risks.

Self-insured malpractice program – VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability via an irrevocable self-insurance trust.

Donor endowments – Donor-restricted gifts where the principal amount is to be held in perpetuity. Distributions of earnings are restricted for use according to the donor's intent, as specified in a gift agreement. Donor endowments typically benefit specific programs in clinical departments of the Medical Center, for either, research, directorships, or general program support.

Split-interest trusts – Trusts established by donors where VUMC is named as beneficiary. Depending on the terms of the trust, VUMC may receive periodic distributions, and potentially a principal amount at some point in the future. Like donor endowments, split-interest trusts typically benefit specific programs as defined in the terms of the trust.

Supplemental executive retirement program assets – Assets set aside to fulfill obligations as they come due according to the terms of the retirement program.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Investments were as follows as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Corporate bonds	\$ 345,781	\$ 336,905
Equity mutual funds	123,707	151,200
Cash and cash equivalents	17,852	27,681
Split-interest trusts	8,515	9,503
Hedged equity mutual funds	137,325	107,548
Fixed income mutual funds	167,261	217,762
Certificates of deposit	18,301	21,162
Asset-backed securities	28,022	28,971
Mortgage-backed securities	6,542	6,503
Commercial paper	22,755	37,040
Government bonds	44,126	53,133
Hedged debt mutual funds	150,056	114,474
Commodities and managed futures mutual funds	42,063	19,802
Target date mutual funds	6,422	5,168
Equity securities	12,033	—
Total investments reported at fair value	1,130,761	1,136,852
Private equity investments recorded at net asset value	31,022	12,839
Multi-strategy funds recorded at net asset value	17,055	—
Hedged equity funds recorded at net asset value	19,073	—
Total investments	<u>\$ 1,197,911</u>	<u>\$ 1,149,691</u>

Investment returns comprise the following elements for Fiscal 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Interest and dividend income	\$ 23,891	\$ 14,910
Net realized gains on sales of securities	9,619	14,922
Realized investment gains	33,510	29,832
Unrealized investment (losses) gains, net	(112,451)	49,995
Total investment returns	(78,941)	79,827
Investment manager, trustee and other fees	(598)	(457)
Restricted investment loss (income)	8,482	(11,169)
Total (loss) income from investments, net	<u>\$ (71,057)</u>	<u>\$ 68,201</u>

VUMC has exposure to risks, including liquidity, interest rate, counterparty, basis, regulatory, market, and credit risks, for marketable securities. Due to the level of risk exposure, it is possible that material near-term valuation changes for investment securities may occur.

VUMC manages all investments, including endowments, in various investment pools.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

10. Property, Plant, and Equipment, Net

Property, plant, and equipment comprise the following as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Land and land improvements	\$ 44,230	\$ 40,800
Buildings and improvements	1,303,474	1,249,125
Equipment and software	813,736	683,108
Leasehold improvements	154,486	141,358
Construction in progress	98,300	94,027
Property, plant, and equipment at cost	2,414,226	2,208,418
Accumulated depreciation and amortization	(734,458)	(578,093)
Property, plant, and equipment, net	<u>\$ 1,679,768</u>	<u>\$ 1,630,325</u>

As part of the MTSA, VUMC acquired land and land improvements and buildings and improvements which are not allowed to be repurposed without the express consent of VU.

In Fiscal 2022 and 2021, VUMC capitalized interest of \$1.3 million and \$2.3 million, respectively, related to long-term capital projects, primarily the VUH lobby and operating room renovations in Fiscal 2022 and the construction of ambulatory and outpatient facilities in Fiscal 2021.

Property, plant, and equipment balances above include the following amounts related to capitalized internal use software:

<i>(\$ in thousands)</i>	2022	2021
Equipment and software	\$ 211,790	\$ 188,334
Construction in progress	3,931	7,095
	215,721	195,429
Accumulated amortization	(85,071)	(58,662)
Internal use software, carrying value	<u>\$ 130,650</u>	<u>\$ 136,767</u>

Depreciation and amortization comprise the following amounts in Fiscal 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Depreciation of tangible assets	\$ 131,677	\$ 117,183
Amortization of finance leases, leasehold improvements, and internal use software	41,322	34,271
Total depreciation and amortization	<u>\$ 172,999</u>	<u>\$ 151,454</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

11. Long-Term Debt

Long-term debt comprises the following as of June 30, 2022 and 2021:

(\$ in thousands)	<u>2022</u> <u>Carrying</u> <u>Amount</u>	<u>2021</u> <u>Carrying</u> <u>Amount</u>	<u>Effective</u> <u>Interest</u> <u>Rate</u> ⁽²⁾	<u>Fiscal</u> <u>Year of</u> <u>Maturity</u>
Series debt				
Fixed-rate debt				
Series 2016A	\$ 476,930	\$ 476,930	4.1%	2047
Series 2016B	300,000	300,000	4.1%	2027
Series 2017A	121,270	121,270	4.1%	2049
Series 2017	100,000	100,000	4.2%	2038
Series 2021A	57,860	—	1.8%	2032
Series 2021B	237,565	—	3.2%	2053
Total fixed-rate debt	<u>1,293,625</u>	<u>998,200</u>	4.1%	
Variable-rate debt				
Series 2016F	21,900	21,900	1.2%	2042
Series 2017B	—	50,000	1.3%	2047
Series 2018	53,385	53,385	0.8%	2050
Series 2021C	50,000	—	1.0%	2047
Total variable-rate debt	<u>125,285</u>	<u>125,285</u>	1.0%	
Total series debt	<u>1,418,910</u>	<u>1,123,485</u>		
Other long-term debt				
2019 Term Loan	35,000	35,000	0.8%	2050
2019 Notes	128,600	128,600	3.9%	2055
2021 Short-Term Loan	—	200,000	0.5%	2022
Subordinated note payable	69,583	74,583	3.2%	2036
Product financing arrangement	20,830	25,121	4.3%	2027
Lines of credit	—	100,000	0.7%	2023
Finance leases	19,388	16,997	2.6%	Various
Total other long-term debt	<u>273,401</u>	<u>580,301</u>	2.3%	
Subtotal ⁽¹⁾	1,692,311	1,703,786	3.4%	
Net unamortized premiums	66,838	53,986		
Net unamortized issuance costs	<u>(12,693)</u>	<u>(10,918)</u>		
Total long-term debt	1,746,456	1,746,854		
Short-term borrowings	—	(300,000)		
Current portion of long-term debt	<u>(18,193)</u>	<u>(14,704)</u>		
Long-term debt, net	<u>\$ 1,728,263</u>	<u>\$ 1,432,150</u>		

(1) The effective interest rate of 3.4% as of June 30, 2022, is presented exclusive of interest rate exchange agreements discussed in Note 12 Interest Rate Exchange Agreements. Inclusive of these agreements, the overall portfolio effective interest rate was 3.8%.

(2) The effective interest rate for each debt instrument is calculated by dividing each instrument's interest expense by the weighted average debt outstanding, and where applicable, interest expense is reduced by premium amortization and increased by original issue discount amortization. Interest rates per the agreements are detailed in the accompanying notes.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

On April 29, 2016, VUMC issued the Series 2016 A, B, C, D, E, and F bonds ("2016 Series Debt") and notes aggregating \$1.3 billion of proceeds for the purpose of financing the Medical Center Acquisition and paying a portion of the costs of issuance associated with the 2016 Series Debt.

The bonds and notes comprising the 2016 Series Debt were issued by the Health and Educational Facilities Board of The Metropolitan Government of Nashville and Davidson County, Tennessee ("HEFB"). As a conduit issuer, the HEFB loaned the debt proceeds to VUMC. VUMC's debt service requirements under these loan agreements coincide with required debt service of the actual HEFB bonds.

- The Series 2016A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$476.9 million and include an original issue premium of \$59.6 million. The Series 2016A bonds have a final maturity date of July 1, 2046, and can be optionally redeemed at par on or after July 1, 2026. The 2016A bonds were structured as serial bonds with maturities from Fiscal 2030 through 2032, as well as three term bonds maturing Fiscal 2036 through 2047, which are subject to mandatory sinking fund redemption in lots. The Series 2016A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2016B taxable fixed-rate revenue bonds were issued in the par amount of \$300.0 million, bearing interest at 4.1% per annum. Interest is paid semiannually on July 1 and January 1, and has a bullet maturity of July 1, 2026. VUMC is entitled, at its option, to redeem all or a portion of the Series 2016B bonds before April 1, 2026, at a make-whole redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 35 basis points above rates for U.S. Treasury securities with comparable maturities.
- The Series 2016F taxable variable-rate revenue bonds were issued in the par amount of \$75.0 million and were placed privately with a bank. The bonds bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2022. During Fiscal 2018, \$53.1 million of the Series 2016F bonds were extinguished using proceeds from the 2018 tax-exempt fixed-rate revenue bonds, discussed further below. The renegotiated interest rate on the remaining \$21.9 million of principal outstanding is a variable-rate mode at a fixed spread to one-month LIBOR of 1.2%. During Fiscal 2022, the Series 2016F taxable variable-rate revenue bonds were modified and the renegotiated interest rate is a variable-rate mode at a fixed spread to SOFR of 0.8%. The remaining principal has a mandatory tender date of December 1, 2028. Prior to that, beginning on July 1, 2022, VUMC must pay annual principal payments ranging from \$2.1 million to \$2.7 million. The remaining \$5.3 million of principal is due on December 1, 2028.
- Prior to Fiscal 2022, Series 2016 C, D and E bonds were extinguished.

On July 26, 2017, the Series 2017A Tax-Exempt and Series 2017 Taxable Corporate Bonds were issued, and on August 1, 2017, the Series 2017B Taxable Revenue Bonds were issued ("2017 Series Debt"), aggregating \$271.3 million of proceeds for the purpose of refinancing existing debt, funding capital projects related to the MCJCHV expansion and the VUH bed expansion/clinical relocation, which was a phased project, and paying a portion of the costs of issuance associated with the 2017 Series Debt.

The Series 2017A Tax-Exempt Revenue Bonds and the Series 2017B Taxable Term Loan Revenue Note were issued by the HEFB. The Series 2017 Taxable Bonds were a corporate issue with VUMC as the issuer.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

- The Series 2017A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$121.3 million and include an original issue premium of \$5.1 million. The final maturity date is July 1, 2048, and optional redemption at par can occur on or after July 1, 2027. The Series 2017A bonds bear interest at 4.4% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2017 taxable fixed-rate corporate bonds were issued in the par amount of \$100.0 million, bearing interest at 4.2% per annum. Interest is paid semiannually on July 1 and January 1, and the bonds have a final maturity date of July 1, 2037. There is a bullet payable beginning July 1, 2026, that allows VUMC to call the debt.
- The Series 2017B taxable variable-rate term loan notes were issued in the par amount of \$50 million and placed privately with a bank. The notes bear interest initially at a fixed-spread to one-month LIBOR of 1.2%. The notes have a final maturity date of July 1, 2046, a tender date of August 1, 2024, and may be redeemed at any time. Proceeds from the issuance of the Series 2017B notes were used to extinguish the Series 2016C R-FLOATs, initially issued on April 29, 2016. During Fiscal 2022, the Series 2017B notes were extinguished using proceeds from the Series 2021C Taxable Revenue Bonds, discussed further below.

On April 20, 2018, the Series 2018 Tax-Exempt Revenue Bonds ("2018 Series Debt") aggregating \$53.4 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2018 Series Debt. The Series 2018 Tax-Exempt Revenue Bonds were issued by the HEFB, were placed privately with a bank, and bear interest at a fixed spread to 81% of one-month LIBOR of 0.6%. The bonds have a final maturity date of July 1, 2049 and can be optionally redeemed on or after July 1, 2025. Proceeds from the issuance of the Series 2018 bonds were used to extinguish a portion of the Series 2016F taxable variable-rate bonds. During Fiscal 2022, the Series 2018 bonds were modified, and the renegotiated interest rate is a fixed spread to 79% of SOFR of 0.6%. The renegotiated bonds have a final maturity date of July 1, 2049 and can be optionally redeemed on or after December 3, 2029.

On July 30, 2019, VUMC entered into a term loan agreement ("2019 Term Loan") with a lender for \$35 million to pay for the acquisition of Tennova – Lebanon (now VWCH) hospital facilities, near term capital expenditures, and costs of issuance. The term loan bears interest at a variable rate plus a fixed spread to one-month LIBOR of 0.50% through the maturity date of August 1, 2029. VUMC has the option to prepay all or a portion of the loan at any time, subject to notice. The 2019 loan is subject to principal amortization commencing on July 1, 2024 and ending July 1, 2049, as defined in the 2019 loan agreement between VUMC and the lender.

On October 22, 2019, the 2019 Taxable Fixed Private Placement Notes ("2019 Notes") aggregating \$128.6 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2019 Notes. The 2019 Notes were placed privately with a bank, and bear interest at a fixed rate of 3.9% per annum. The notes have a final maturity date of July 1, 2054.

On April 9, 2020, the 2020 Taxable Fixed Term Loan ("2020 Loan") aggregating \$300 million was issued to provide additional liquidity during the COVID-19 pandemic. The lender for the 2020 Loan was JPMorgan Chase Bank. The debt bore interest at a fixed rate of 2.1% per annum, had an optional redemption after one year, and had a final maturity date of April 1, 2022. During Fiscal 2021, the 2020 Loan was extinguished using proceeds from the 2021 Short-Term Loan discussed further below, and draws on available lines of credit.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

On April 9, 2021, the 2021 Short-Term Loan was issued in the par amount of \$200.0 million for the purpose of refinancing the 2020 Loan. The lender for the 2021 Short-Term Loan was Royal Bank of Canada. The debt bore interest at a fixed spread to LIBOR of 0.4% and had a maturity of April 8, 2022. During Fiscal 2022, the 2021 Short-Term Loan was extinguished using proceeds from the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds discussed further below.

On November 4, 2021, the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds were issued, and on December 1, 2021, the Series 2021C Taxable Revenue Bonds were issued ("2021 Series Debt"), aggregating \$345.4 million of proceeds for the purpose of refinancing existing debt, funding capital projects, and paying a portion of the costs of issuance associated with the 2021 Series Debt. The 2021 Series was issued by the HEFB.

- The Series 2021A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$57.9 million and include an original issue premium of \$16.2 million. The Series 2021A bonds have a bullet maturity of July 1, 2031, and can be optionally redeemed at par on or after January 1, 2031. The Series 2021A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The 2021B taxable fixed-rate revenue bonds were issued in the par amount of \$237.6 million, bearing interest at 3.2% per annum, which is paid semiannually on July 1 and January 1. The 2021B bonds have a final maturity of July 1, 2052 and are subject to mandatory sinking fund redemption in lots. VUMC is entitled, at its option, to redeem all or a portion of the Series 2021B bonds before January 1, 2052, at a redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 20 basis points above rates for U.S. Treasury securities with comparable maturities.
- The 2021C taxable variable-rate revenue bonds were issued in the par amount of \$50.0 million and were placed privately with a bank. The bonds bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 0.5%. The bonds have a final maturity date of July 1, 2046, a tender date of December 1, 2027, and may be redeemed at any time. Proceeds from the issuance of the Series 2021C bonds were used to extinguish the Series 2017B notes.

Each of the bonds, notes, and loans represent separate obligations under a Master Trust Indenture ("MTI") structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group; presently, VUMC has no other third-party members participating in the obligated group. All debt issued under the MTI is a general obligation of the obligated group. Under the provisions of the Leasehold Deed of Trust, Security Agreement, Assignment of Rents and Leases, and Fixture Filing (the "Security Agreement") within the MTI, gross receivables of the obligated group are pledged as collateral. Additionally, the Security Agreement established a mortgage lien on (i) the leasehold interest of the land subject to the Ground Lease; (ii) the buildings, structures, improvements, and fixtures now or hereafter located on the land subject to the Ground Lease; and (iii) certain other collateral.

Trust indentures for certain bond issues contain covenants and restrictions, the most material of which include limitations on the issuance of additional debt, maintenance of a specified debt service coverage ratio, and a minimum amount of days cash on hand. VUMC complied with such covenants and restrictions as of June 30, 2022 and 2021.

On April 29, 2016, VUMC delivered a secured subordinated promissory note in the amount of \$100.0 million to VU to finance the Acquisition (the "subordinated note"). In July of 2018, VU sold its rights to future principal and interest payments on this note to a third party. The note was issued at

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

a fixed rate of 3.25% with monthly principal payments totaling \$5.0 million annually commencing on May 31, 2016, for a period of 20 years ending on April 30, 2036. VUMC may, at any time and from time to time, without premium or penalty, prepay all or any portion of the unpaid principal amount of the subordinated note. This note is secured by the gross receivables and mortgaged property described in the Security Agreement subject to the requirements of the 2016 Series Debt and the MTI.

As part of the Acquisition, VUMC assumed a 10-year, unsecured, noninterest-bearing product financing arrangement with a vendor for the purchase and implementation of internal use software. The annual payment of \$5.3 million is payable in monthly installments, is considered principal and imputed interest, and continues through Fiscal 2027. The balance due under the Product Financing Arrangement is \$20.8 million and \$25.1 million as of June 30, 2022 and 2021, respectively. At June 30, 2022 and 2021, \$4.5 million and \$4.3 million, respectively, was included in the current portion of long-term debt caption, with the remaining balance in long-term debt, net of current portion.

In Fiscal 2022 and 2021, noncash investing and financing activities totaled \$10.5 million and \$6.8 million, respectively, related to finance leases.

VUMC has an agreement with a bank to provide a general use line of credit with a maximum available commitment totaling \$100.0 million, which bears interest at a fixed spread to one-month LIBOR of 0.65% and has no maturity date if the line of credit is renewed annually. The outstanding balance on the line of credit is \$59.5 million as of June 30, 2021. During Fiscal 2022, the outstanding balance of the general use line of credit was paid off using proceeds from the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds, discussed previously. The line of credit accrues a commitment fee of 0.15% per annum on any unused portion of the line of credit. Effective April 4, 2022, the agreement was amended to modify the interest rate and commitment fee and extend the maturity date. The line of credit bears interest at a fixed spread to SOFR of 0.60%, accrues a commitment fee of 0.10% on any unused portion of the line of credit, and has a final maturity date of April 3, 2023.

VUMC established one additional line of credit with a bank in Fiscal 2021. A \$50 million line of credit with Royal Bank of Canada, bearing interest at a fixed spread to one-month LIBOR of 0.45%, maturing in Fiscal 2022 with a commitment fee of 0.2% on any unused portion of the line of credit. As of June 30, 2021, this line of credit had an outstanding balance of \$40.5 million. During Fiscal 2022, the outstanding balance of the line of credit was paid off using proceeds from the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds, discussed previously. Effective April 8, 2022, the agreement was amended to modify the interest rate and extend the maturity date. The line of credit bears interest at a fixed spread to SOFR of 0.45% and has a maturity date of April 7, 2023.

During Fiscal 2020, VUMC established an additional \$50 million line of credit with Truist, bearing interest at a fixed spread to one-month LIBOR of 1.0%, maturing in Fiscal 2022 with a commitment fee of 0.25% on any unused portion of the line of credit. As of June 30, 2021, this line of credit had no outstanding balance. This line of credit expired during Fiscal 2022.

The total outstanding balance on lines of credit is \$100.0 million as of June 30, 2021. There is no outstanding balance on lines of credit as of June 30, 2022. Commitment fees for the lines of credit totaled \$0.3 million and \$0.4 million in Fiscal 2022 and Fiscal 2021, respectively.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Interest paid on all obligations, including interest rate swap settlements, net of amounts capitalized, was \$62.6 million and \$68.4 million in Fiscal 2022 and 2021, respectively.

Principal retirements and scheduled sinking fund requirements based on nominal maturity schedules for long-term debt due in subsequent fiscal years ending June 30 are as follows:

(\$ in thousands)

2023	\$ 18,193
2024	17,319
2025	17,009
2026	19,980
2027	317,167
Thereafter	1,302,643
	<u>\$ 1,692,311</u>

12. Interest Rate Exchange Agreements

Key features of VUMC interest rate exchange agreements are summarized below:

<u>Notional Amount</u>	<u>Pay Fixed Rate</u>	<u>Receive Variable Rate</u>	<u>Mandatory Termination Date</u>
\$75.0 million	4.28%	68% of one-month LIBOR	April 29, 2026
\$75.0 million	4.18%	68% of one-month LIBOR	April 29, 2023

VUMC incorporates these interest rate exchange agreements into its debt portfolio management strategy. There are no collateral pledging requirements. The agreements terminate automatically on April 29, 2026 and 2023, if not renegotiated or extended, at which point the exchange agreements will be settled at fair value.

VUMC recorded the following activity related to the interest rate exchange agreements during Fiscal 2022 and 2021:

(\$ in thousands)

	<u>2022</u>	<u>2021</u>
Mark-to-market adjustments	\$ 31,845	\$ 23,478
Cash settlements	(6,004)	(6,106)
Unrealized gain on interest rate exchange agreements, net of cash settlements	<u>\$ 25,841</u>	<u>\$ 17,372</u>

13. Leases

VUMC has operating and finance leases for real estate, personal property and equipment. VUMC determines if an arrangement is a lease at the inception of a contract. Leases with an initial term of twelve months or less are not recorded in the consolidated balance sheets.

VUMC has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, VUMC elected the permitted practical expedients to not reassess the

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.

Right-of-use assets represent VUMC's right to use an underlying asset during the lease term, and lease liabilities represent VUMC's obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date, based on the net present value of fixed lease payments over the lease term. VUMC's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of VUMC's operating leases do not provide an implicit rate, VUMC uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. VUMC considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term. Variable lease costs consist primarily of common area maintenance and other index adjustments.

Operating and finance lease right-of-use assets and lease liabilities as of June 30, 2022 and 2021, are as follows:

(\$ in thousands)	Balance Sheet Classification	2022	2021
Assets:			
Operating leases	Operating leases	\$ 826,560	\$ 839,850
Finance leases	Property, plant, and equipment, net	19,412	17,363
Total lease assets		<u>\$ 845,972</u>	<u>\$ 857,213</u>
Liabilities:			
Current:			
Operating leases	Current portion of operating lease liabilities	\$ 68,510	\$ 67,343
Finance leases	Current portion of long-term debt	6,618	5,413
Noncurrent:			
Operating leases	Noncurrent portion of operating lease liabilities	783,178	795,330
Finance leases	Long-term debt, net of current portion	12,770	11,584
Total lease liabilities		<u>\$ 871,076</u>	<u>\$ 879,670</u>
Weighted-average remaining term:			
Operating leases		56.3 years	57.4 years
Finance leases		3.4 years	3.6 years
Weighted-average discount rate:			
Operating leases		3.7%	3.7%
Finance leases		2.7%	2.4%

Included in the tables above is the Ground Lease with VU expiring in 2114 discussed below. Excluding this lease, the weighted average remaining lease term for VUMC's operating leases is 7.5 years as of June 30, 2022 and 8.2 years as of June 30, 2021. As of June 30, 2022 and 2021, the

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

land lease comprises \$488.7 million and \$489.2 million, respectively, of the operating lease asset and \$491.4 million and \$491.9 million, respectively, of the operating lease liability detailed above.

Lease expense for finance and operating leases for the years ended June 30, 2022 and 2021, are as follows:

<i>(\$ in thousands)</i>	2022	2021
Finance lease expense:		
Amortization of leased assets	\$ 8,431	\$ 6,125
Interest on lease liabilities	467	410
Operating lease expense ⁽¹⁾	107,551	109,665
Short-term lease expense ⁽¹⁾	4,551	4,578
Variable lease expense ⁽¹⁾	15,665	16,181
	<u>\$ 136,665</u>	<u>\$ 136,959</u>

⁽¹⁾ Expense is included in "Facilities and equipment" in the consolidated statements of operations.

The following table presents supplemental cash flow information for the years ended June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 105,366	\$ 105,136
Operating cash flows for finance leases	467	410
Financing cash flows for finance leases	7,333	5,766

The following table reconciles the undiscounted minimum lease payments to the operating and financing lease liabilities recorded in the consolidated balance sheet at June 30, 2022:

<i>(\$ in thousands)</i>	Operating Leases	Finance Leases
2023	\$ 96,040	\$ 6,974
2024	87,268	5,733
2025	79,137	4,066
2026	66,484	1,555
2027	51,993	1,569
Thereafter	1,812,846	371
Total minimum lease payments	2,193,768	20,268
Less: amount of lease payments representing interest	(1,342,080)	(880)
Present value of future minimum lease payments	851,688	19,388
Less: current lease obligations	(68,510)	(6,618)
Long-term lease obligations	<u>\$ 783,178</u>	<u>\$ 12,770</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Essential provisions of leases considered by management to be material are as follows:

- On April 29, 2016, VUMC entered into a Ground Lease with VU for approximately 1.7 million square feet of land for an initial term ending June 30, 2114, and an option to extend for up to two additional terms of 50 to 99 years each upon agreement by VU and VUMC. The annual base rent is payable monthly, and is CPI adjusted annually. VUMC made rental payments totaling \$20.4 million and \$19.6 million in Fiscal 2022 and 2021, respectively. The Ground Lease allows VUMC to use the land on which its campus and related buildings are located. Included in the table above are \$1.8 billion in ground lease payments representing future minimum rentals based on the initial annual base rent of \$19.4 million, excluding annual CPI adjustments.
- In July 2007, VU entered into an agreement to lease approximately 50% of the space in the 850,000 square foot One Hundred Oaks shopping center located approximately five miles from the main campus ("100 Oaks Lease"). VU redeveloped this leased space primarily for medical and office uses. In October 2014, VU agreed to an amendment which extends the original lease term to November 30, 2035, with an option to renew the lease further for four additional 10-year periods. As part of the lease agreement, the lessee also has first rights on leasing additional space in the shopping center and first rights on purchasing if the landlord desires to sell. On April 29, 2016, the 100 Oaks Lease was assigned to VUMC. VUMC included minimum property rental payments totaling \$104.4 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VU assigned to VUMC a lease for approximately 231,000 square feet of office space at 2525 West End Avenue with expiration dates ranging from 2026 through 2030, with options to renew for two additional five-year periods. VUMC included minimum lease payments totaling \$56.0 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VUMC and VU entered into certain lease agreements for the use of space in buildings owned by both entities. As of June 30, 2022, VUMC's estimated future minimum lease payments to VU totaled \$33.3 million. Estimated future lease receipts from VU for the fiscal year ended June 30, 2023, are \$7.9 million, subject to annual renewal.

14. Net Assets

Net asset restrictions relate to the following purposes as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Donor-restricted – time or purpose		
Property, plant, and equipment	\$ 8,294	\$ 13,044
Research and education	150,086	115,897
Operations	11,575	15,087
Total donor-restricted – time or purpose	<u>\$ 169,955</u>	<u>\$ 144,028</u>
Donor restricted – perpetuity		
Research and education	<u>\$ 98,477</u>	<u>\$ 80,530</u>

Net assets without donor restrictions are free of donor-imposed restrictions. This classification includes all revenues, gains, and losses not restricted by donors. VUMC reports all expenditures in net assets without donor restrictions since the use of restricted contributions in accordance with donors' stipulations results in the release of the restriction.

Donor restricted – time or purpose contain donor-imposed stipulations that expire with the passage of time or that can be satisfied by the action of VUMC. These net assets may include restricted gifts including unconditional pledges, split-interest agreements, interests in trusts held by others, and accumulated appreciation on donor-restricted endowments not yet appropriated by the Board of Directors for distribution. Donor gifts that are restricted for funding capital projects are considered released from restriction once related capital expenditures have been made and the asset is placed in service.

Donor restricted – perpetuity contains amounts held in perpetuity as requested by donors. These net assets may include unconditional pledges, donor-restricted endowments, split-interest agreements, and interests in trusts held by others. Generally, the donors of these assets permit VUMC to use a portion of the income earned on related investments for specific purposes.

UPMIFA specifies that unless stated otherwise in a gift instrument, donor-restricted assets in an endowment fund are restricted assets until appropriated for expenditure. Barring the existence of specific instructions in gift agreements for donor-restricted endowments, VUMC reports the historical value of such endowments as donor restricted – perpetuity and the net accumulated appreciation as donor restricted – time or purpose. In this context, the historical value represents the original value of initial contributions restricted as permanent endowments plus the original value of subsequent contributions and, if applicable, the value of accumulations made in accordance with the direction of specific donor gift agreements.

15. Fair Value Measurements

Fair value measurements represent the amount at which the instrument could be exchanged in an orderly transaction between market participants at the measurement date. VUMC utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels:

- | | |
|---------|---|
| Level 1 | Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that VUMC has the ability to access. |
| Level 2 | Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the assets or liabilities, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
| Level 3 | Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect VUMC's assumptions about the inputs market participants would use in pricing the asset or liability, including assumptions about risk. Unobservable inputs are developed based on the best information available in the circumstances and may include VUMC's own data. |

VUMC's principal assets and liabilities are cash and cash equivalents, investments, patient accounts receivable, estimated receivables and liabilities under third-party programs, grants and contracts receivable, pledges receivable, operating lease assets, accounts payable and other accrued expenses, self-insurance reserves, operating lease liabilities, long-term debt, and interest rate exchange agreements. Except for long-term debt, the carrying amount of these assets and liabilities approximates fair value.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

As of June 30, 2022, the carrying value and estimated fair value of total long-term debt totaled \$1.7 billion and \$1.7 billion, respectively. As of June 30, 2021, the carrying value and estimated fair value of total long-term debt totaled \$1.7 billion and \$1.9 billion, respectively. VUMC bases estimated fair value of long-term debt on market conditions prevailing at fiscal year-end reporting dates. Besides potentially volatile market conditions, fair value estimates typically reflect limited secondary market trading. The fair values of the fixed-rate Series Debt, as defined in Note 11 Long-Term Debt, were based on a Level 2 computation using quoted prices for similar liabilities in active markets as of June 30, 2022 and 2021, as applicable. The carrying amounts related to VUMC's variable-rate Series Debt and other long-term debt obligations approximate their fair values as of June 30, 2022 and 2021. As of June 30, 2022 and 2021, the fair values of the subordinated note payable and the product financing arrangement were based on a Level 2 discounted cash flow approach applying a risk-adjusted spread for issuers of similar credit quality to U.S. Treasury yields for securities with comparable maturities.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

For financial instruments measured at fair value on a recurring basis, the following tables summarize valuation hierarchy levels as of June 30, 2022 and 2021, determined by the nature of the financial instrument and the least observable input significant to the fair value measurement:

Fair Value Measurements as of June 30, 2022				
<i>(\$ in thousands)</i>	Level 1	Level 2	Level 3	Total Carrying Amount
Assets				
Corporate bonds	\$ 19,004	\$ 326,777	\$ —	\$ 345,781
Equity mutual funds	19,887	103,820	—	123,707
Cash and cash equivalents	17,055	797	—	17,852
Beneficial interests in split-interest trusts	—	8,515	—	8,515
Hedged equity mutual funds	—	137,325	—	137,325
Fixed-income mutual funds	80,697	86,564	—	167,261
Certificates of deposit	—	18,301	—	18,301
Asset-backed securities	6,680	21,342	—	28,022
Mortgage-backed securities	—	6,542	—	6,542
Commercial paper	—	22,755	—	22,755
Government bonds	10,498	33,628	—	44,126
Hedged debt mutual funds	—	150,056	—	150,056
Commodities and managed futures mutual funds	8,135	33,928	—	42,063
Target date mutual funds	—	6,422	—	6,422
Equity securities	12,033	—	—	12,033
Total assets in the fair value hierarchy	<u>\$ 173,989</u>	<u>\$ 956,772</u>	<u>\$ —</u>	<u>\$ 1,130,761</u>
Investments measured at net asset value				67,150
Total assets reported at fair value				<u>\$ 1,197,911</u>
Liabilities				
Interest rate exchange agreements	\$ —	\$ 45,019	\$ —	\$ 45,019
Total liabilities reported at fair value	<u>\$ —</u>	<u>\$ 45,019</u>	<u>\$ —</u>	<u>\$ 45,019</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Fair Value Measurements as of June 30, 2021				
(\$ in thousands)	Level 1	Level 2	Level 3	Total Carrying Amount
Assets				
Corporate bonds	\$ 38,310	\$ 298,595	\$ —	\$ 336,905
Equity mutual funds	29,174	122,026	—	151,200
Cash and cash equivalents	27,681	—	—	27,681
Beneficial interests in split-interest trusts	—	9,503	—	9,503
Hedged equity mutual funds	—	107,548	—	107,548
Fixed-income mutual funds	114,871	102,891	—	217,762
Certificates of deposit	—	21,162	—	21,162
Asset-backed securities	6,982	21,989	—	28,971
Mortgage-backed securities	—	6,503	—	6,503
Commercial paper	—	37,040	—	37,040
Government bonds	21,884	31,249	—	53,133
Hedged debt mutual funds	—	114,474	—	114,474
Commodities and managed futures mutual funds	10,759	9,043	—	19,802
Target date mutual funds	—	5,168	—	5,168
Total assets in the fair value hierarchy	<u>\$ 249,661</u>	<u>\$ 887,191</u>	<u>\$ —</u>	<u>\$ 1,136,852</u>
Investments measured at net asset value				12,839
Total assets reported at fair value				<u>\$ 1,149,691</u>
Liabilities				
Interest rate exchange agreements	\$ —	\$ 76,864	\$ —	\$ 76,864
Total liabilities reported at fair value	<u>\$ —</u>	<u>\$ 76,864</u>	<u>\$ —</u>	<u>\$ 76,864</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Certain of the investments are reported using a calculated NAV per share. These investments are not expected to be sold at amounts that are materially different from NAV. The following table identifies attributes relating to the nature and risk of investments for which fair value is determined using a calculated NAV as of June 30, 2022 and 2021:

June 30, 2022				
(\$ in thousands)	Carrying Amount	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Private equity	\$ 31,022	\$ 3,500	None	None
Multi-strategy hedge funds	17,055	8,000	Quarterly	65-95 Days
Hedged equity funds	19,073	—	Quarterly	90 Days
Total	\$ 67,150	\$ 11,500		

June 30, 2021				
(\$ in thousands)	Carrying Amount	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Private equity	\$ 12,839	\$ —	None	None

VUMC employs derivatives, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable-rate debt. In addition to the credit risk of the counterparty owing a balance, VUMC calculates the fair value of interest rate exchange agreements based on the present value of future net cash settlements that reflect market yields as of the measurement date.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as the risk of credit loss in the event of nonperformance by the counterparty. VUMC deals only with high-quality counterparties that meet rating criteria for financial stability and credit-worthiness.

16. Retirement Plan

VUMC's full-time employees participate in a 403(b) defined contribution retirement plan administered by a third party. For eligible employees with one year of continuous service, this plan requires employer matching of employee contributions up to 5% of eligible compensation. The employee immediately vests in these contributions.

VUMC funds the obligations under this plan through monthly transfers to the respective retirement plan administrator with the corresponding expense recognized in the year incurred. During Fiscal 2022 and 2021, VUMC recognized \$86.4 million and \$76.8 million, respectively, of expense in connection with this plan.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

17. Functional Expense

VUMC provides general health care services primarily to residents within its geographic location and supports research and education programs. Total operating expense by nature and function for Fiscal 2022 and 2021 were as follows:

(\$ in thousands)

	For the year ended June 30, 2022			
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits	\$ 2,454,835	\$ 608,296	\$ 241,202	\$ 3,304,333
Supplies and drugs	1,321,793	67,058	38,088	1,426,939
Facilities and equipment	187,646	41,496	77,236	306,378
Services and other	677,021	147,922	94,462	919,405
Depreciation and amortization	150,181	1,140	21,678	172,999
Interest	50,391	9,527	12	59,930
Total operating expense	<u>\$ 4,841,867</u>	<u>\$ 875,439</u>	<u>\$ 472,678</u>	<u>\$ 6,189,984</u>

(\$ in thousands)

	For the year ended June 30, 2021			
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits	\$ 2,021,532	\$ 581,945	\$ 233,067	\$ 2,836,544
Supplies and drugs	1,134,657	56,507	25,039	1,216,203
Facilities and equipment	177,973	44,722	74,053	296,748
Services and other	599,477	107,610	88,200	795,287
Depreciation and amortization	128,181	1,582	21,691	151,454
Interest	49,351	11,163	16	60,530
Total operating expense	<u>\$ 4,111,171</u>	<u>\$ 803,529</u>	<u>\$ 442,066</u>	<u>\$ 5,356,766</u>

Certain expense categories are attributable to more than one function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, wages, and benefits, and services and other.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

18. Commitments and Contingencies

Management has policies, procedures, and an organizational structure to enforce and monitor compliance with government statutes and regulations. VUMC's compliance with such laws and regulations is subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time.

- **Litigation.** VUMC is a defendant in certain lawsuits alleging medical malpractice and civil action.

Through the operation of its compliance program, VUMC from time to time initiates the review of billing for clinical services provided by VUMC and its affiliated providers. VUMC has established a liability reserve relating to certain matters under review as of June 30, 2022 and 2021, which is not material to VUMC's overall financial position.

- **Regulations.** VUMC's compliance with regulations and laws is subject to future government reviews and interpretations, as well as regulatory actions unknown at this time. VUMC believes that the liability, if any, from such reviews will not have a significant effect on VUMC's consolidated financial position.
- **Medical Malpractice Self-Insurance.** The consolidated balance sheets include reserves for medical malpractice, professional, and general liability coverage totaling \$81.6 million as of June 30, 2022, and \$72.6 million as of June 30, 2021. These liabilities are measured at the net present value of those cash flows using a discount rate of 2.5% at both dates and are classified as current or noncurrent based on the expected timing of cash flows. Other current assets include expected recoveries from commercial insurance carriers under excess coverage arrangements totaling \$5.9 million as of June 30, 2022, and \$3.8 million as of June 30, 2021. During Fiscal 2022 and 2021, VUMC recorded expenses for medical malpractice self-insurance of \$30.4 million and \$22.4 million, respectively.
- **Employee Health and Workers' Compensation Insurance.** Accrued compensation and benefits included actuarially determined liabilities for employee health and workers' compensation claims totaling \$23.0 million and \$5.7 million, respectively, as of June 30, 2022, and \$21.8 million and \$6.7 million, respectively, as of June 30, 2021. During Fiscal 2022 and 2021, VUMC recorded expenses for self-insured employee health benefit plans, net of employee premiums, totaling \$261.4 million and \$241.9 million, respectively. During Fiscal 2022 and 2021, VUMC recorded expenses for self-insured workers' compensation plans of \$4.9 million.
- **Federal and State Contracts and Other Requirements.** Expenditures related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. Amounts of expenditures that granting agencies might disallow cannot be determined at this time. These amounts affect government grants and contracts revenue, as well as facilities and administrative costs recovery. VUMC does not expect these costs to impact the consolidated financial position by material amounts.
- **Health Care Services.** In Fiscal 2022 and 2021, 84% and 85%, respectively, of VUMC's operating revenue was generated by providing health care services, where revenue is affected by reimbursement arrangements with federal and state healthcare programs, commercial insurance, and other managed care payors. If reimbursement rates from third-party payors decrease or if contract terms become less favorable in future periods, VUMC's operating revenues may decline. See Note 4 Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements, for further information regarding healthcare revenues and related receivables.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

- **HIPAA Compliance.** Under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), the federal government has authority to complete fraud and abuse investigations. HIPAA has established substantial fines and penalties for offenders. VUMC maintains policies, procedures, and organizational structures to enforce and monitor compliance with HIPAA, as well as other applicable local, state, and federal statutes and regulations.
- **Construction.** VUMC had contractual commitments under major construction and equipment contracts totaling \$53.5 million and \$56.8 million as of June 30, 2022 and 2021, respectively.

19. Other Events

COVID-19

In March of Fiscal 2020, COVID-19, a disease caused by the novel strain of the coronavirus, was designated by the World Health Organization as a global pandemic. A state of emergency was subsequently announced by the State of Tennessee, quickly followed by “stay at home” orders and orders for hospitals and outpatient surgical facilities to stop non-essential procedures. This global health crisis negatively impacted many facets of the business, including lower patient volumes and related revenues, significant increases in certain supply costs (in particular personal protective equipment) as well as difficulties sourcing these supplies, and volatility in the U.S. and global financial markets impacting VUMC’s investment portfolios. Due to new strains and periodic surges in coronavirus cases, VUMC continued to experience negative impacts to its business in Fiscal 2021 and 2022.

Sources of pandemic relief include the federal stimulus package known as The Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, signed into law on March 27, 2020, the Coronavirus Response and Consolidated Appropriations Act (“CRCA”) signed into law on December 27, 2020, and the American Rescue Plan (“ARP”), signed into law on March 11, 2021. These laws include a number of provisions: most importantly providing funding through the Public Health and Social Services Emergency Fund (“Provider Relief Fund”) to reimburse eligible health care providers for health care-related expenses or lost revenues not otherwise reimbursed that are directly attributable to COVID-19. These provider relief funds included amounts distributed to providers based on their share of the Medicare fee-for-service reimbursement (“General Distributions”). The funds also included for certain targeted distributions (“Targeted Distributions”) to qualifying providers (primarily rural and high impact areas). For the period ended June 30, 2022, VUMC recognized as revenue approximately \$44.8 million in General Distributions and \$23.4 million in Targeted Distributions, for a total of \$68.2 million, under the Provider Relief Fund. For the period ended June 30, 2021, VUMC recognized as revenue approximately \$46.3 million in General Distributions and \$8.8 million in Targeted Distributions, for a total of \$55.1 million, under the Provider Relief Fund. These amounts are presented in other operating revenue in the consolidated statements of operations.

In addition, the CARES Act provides for an expansion of the Medicare Accelerated and Advance Payment Program (“MAAPP”) whereby inpatient acute care hospitals and other eligible providers may request an advance payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments beginning 120 days after receipt. During Fiscal 2020, VUMC received advance payments from Medicare of \$222.4 million.

On October 1, 2020, the Continuing Appropriations and Other Extensions Acts amended the repayment terms for the funds received under the MAAPP. Under the revised repayment terms, the Centers for Medicare and Medicaid Services (“CMS”) began to automatically recoup the advance payments one year from the original date of issuance by offsetting the payments against newly

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

submitted Medicare claims. Once the recoupment period began, for the first eleven (11) months, Medicare automatically recouped payments at a rate of 25% of the Medicare claims amount otherwise owed to VUMC. After the first recoupment period of eleven (11) months, and continuing for the following six (6) months, Medicare automatically recoups payments at a rate of 50% of the Medicare claims amount otherwise owed to VUMC. After this repayment term concludes, any balance that remains outstanding will be subject to interest at a rate of four percent (4%) per annum. In accordance with the repayment terms, CMS began recoupment of VUMC's MAAPP funds in April 2021 and recouped \$33.0 million as of June 30, 2021. CMS recouped an additional \$173.4 million during Fiscal 2022. VUMC expects the remaining liability will be subject to recoupment within the next twelve months, and as such, VUMC has classified the remaining MAAPP liability of \$16.0 million as a current liability in the consolidated balance sheet as of June 30, 2022.

The CARES Act also allows for deferred payment of the employer portion of certain payroll taxes between March 27, 2020 and December 31, 2020, with 50% due December 31, 2021 and the remaining 50% due December 31, 2022. As of June 30, 2022, VUMC had deferred payroll tax payments of \$37.9 million included in accrued compensation and benefits in the consolidated balance sheet. As of June 30, 2021, VUMC had deferred payroll tax payments of \$75.8 million, with \$37.9 million and \$37.9 million included in accrued compensation and benefits and other noncurrent liabilities, respectively, in the consolidated balance sheet.

In addition, the CARES Act suspended the sequestration payment adjustment percentage of 2% applied to all Medicare Fee-for-Service claims from May 1, 2020 through December 31, 2020, with subsequent acts extending through March 31, 2022. Upon conclusion of the suspension period, CMS applied a 1% payment adjustment for the period April 1, 2022 through June 30, 2022, at which time CMS will revert to the 2% payment adjustment for sequestration. This suspension positively impacted patient service revenue in the consolidated statements of operations by approximately \$14 million for Fiscal 2022 and 2021. Beginning, September 1, 2020, the CARES Act also provided for a 20% Medicare supplement for Medicare patients diagnosed with COVID-19 that are admitted to the hospital, reflecting the additional costs of treating a patient with this diagnosis. During Fiscal 2022 and 2021, VUMC recognized an additional \$6 million in patient service revenue in the consolidated statements of operations related to this supplement.

During Fiscal 2022, VUMC received \$73.2 million of supplemental payments directed from the State of Tennessee which covered a uniform increase for inpatient and outpatient services performed for the period January 1, 2022 through December 31, 2022. VUMC recognized \$36.6 million as patient service revenue related to the services performed for the period January 1, 2022 through June 30, 2022. The remaining \$36.6 million of payments received was deferred and is included in the current liability section as an estimated liability under third-party programs in the consolidated balance sheet as of June 30, 2022. This deferred amount will be recognized during Fiscal 2023.

During Fiscal 2022, VUMC recognized as other operating revenue \$4.5 million for Tennessee staffing grants. During Fiscal 2021, VUMC recognized as other operating revenue \$3.1 million for Tennessee staffing grants, \$2.0 million of business interruption insurance payments, \$2.0 million of State of Tennessee CARES funding, and \$0.8 million of other COVID-19 grants.

Acquisition of VBCH and VTHH

Effective January 1, 2021, VUMC acquired from CHS: Tennova Healthcare – Shelbyville and Tennova Healthcare – Harton, now known as Vanderbilt Bedford Hospital ("VBCH") and Vanderbilt Tullahoma-Harton Hospital ("VTHH") for total consideration of \$15.6 million.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

The following table summarizes the fair value of net assets acquired:

(\$ in thousands)

Inventories	\$ 2,808
Other current assets	882
Property, plant, and equipment, net	11,943
Operating lease assets	4,230
Other noncurrent assets	122
Accounts payable and other accrued expenses	(155)
Operating lease liabilities	(4,230)
Total invested capital	<u>\$ 15,600</u>

The results of operations for these acquisitions are included in the consolidated statements of operations and changes in net assets beginning on the acquisition date. Pro forma results of operations and changes in net assets as though these acquisitions occurred on July 1, 2020 are not materially different and accordingly are not provided.

Acquisition of Noncontrolling Interest in VMH

As discussed in Note 1 Description of Organization, effective January 1, 2021, VUMC acquired a noncontrolling ownership interest of 20% in CHS's affiliated Tennova Healthcare – Clarksville for total consideration of \$36.9 million. The noncontrolling interest is accounted for as an equity method investment and is included in other noncurrent assets in the consolidated balance sheets.

Business Combination of Cool Springs Surgery Center

Effective July 1, 2021, VUMC amended the operating agreement related to the noncontrolling ownership interest held in the Cool Springs Surgery Center ("CSSC"). This amendment constituted a change in control event for CSSC and is now consolidated into the financial statements of VUMC. Prior to the change in control event date, VUMC accounted for its noncontrolling ownership interest in CSSC as an equity method investment. In accordance with FASB ASC 805, Business Combinations, the acquisition method was applied to account for this consolidation and CSSC was recorded at its fair value.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

The following table summarizes the fair values of the assets acquired and liabilities assumed:

(\$ in thousands)

Cash	\$	3,319
Patient accounts receivable		1,965
Inventories		832
Other current assets		205
Property, plant, and equipment, net		3,489
Total identifiable assets acquired		<u>9,810</u>
Accounts payable and other accrued expenses		(848)
Medicare accelerated payments		(957)
Accrued compensation and benefits		(408)
Long-term debt		(132)
Total liabilities assumed		<u>(2,345)</u>
Net identifiable assets acquired		7,465
Goodwill		<u>27,028</u>
Net assets acquired	\$	<u><u>34,493</u></u>

The acquisition-date fair value of the previous equity interest was \$18.0 million. VUMC recognized a gain of \$14.7 million as a result of remeasuring its previous equity interest to fair value, which is presented in other nonoperating gains in the consolidated statements of operations.

20. Subsequent Events

Management evaluated events after June 30, 2022 through September 30, 2022, the date on which the consolidated financial statements were issued. During this period, there were no subsequent events requiring recognition or disclosure in the consolidated financial statements that have not been recorded or disclosed.

Report of Independent Auditors on Supplementary Information

The Board of Directors
Vanderbilt University Medical Center

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying Vanderbilt University Medical Center consolidating balance sheets and consolidating statements of operations are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Ernst & Young LLP

September 30, 2022

Vanderbilt University Medical Center
Consolidating Balance Sheet
June 30, 2022

(\$ in thousands)	Obligated Group	Nonobligated Entity	Eliminations	Consolidated
Assets				
Current assets:				
Cash and cash equivalents	\$ 575,892	\$ 75,828	\$ —	\$ 651,720
Intercompany receivable	171,231	—	(171,231)	—
Current investments	255,090	—	—	255,090
Patient accounts receivable	643,840	14,804	—	658,644
Grants and contracts receivable	88,775	18	—	88,793
Inventories	129,968	4,589	—	134,557
Other current assets	94,439	28,464	—	122,903
Total current assets	1,959,235	123,703	(171,231)	1,911,707
Restricted cash	17,744	918	—	18,662
Noncurrent investments	785,234	—	(12,000)	773,234
Noncurrent investments limited as to use	150,925	—	—	150,925
Property, plant, and equipment, net	1,632,827	46,941	—	1,679,768
Operating lease assets	813,633	12,927	—	826,560
Other noncurrent assets	84,644	82,090	—	166,734
Total assets	<u>\$ 5,444,242</u>	<u>\$ 266,579</u>	<u>\$ (183,231)</u>	<u>\$ 5,527,590</u>
Liabilities and Net Assets				
Current liabilities:				
Current portion of long-term debt	\$ 16,832	\$ 1,361	\$ —	\$ 18,193
Intercompany payable	—	171,231	(171,231)	—
Accounts payable and other accrued expenses	375,099	28,960	—	404,059
Medicare accelerated payments	15,959	(3)	—	15,956
Estimated liabilities under third-party programs	88,855	473	—	89,328
Accrued compensation and benefits	342,780	10,490	—	353,270
Current portion of operating lease liabilities	64,883	3,627	—	68,510
Current portion of deferred revenue	8,552	942	—	9,494
Current portion of medical malpractice self-insurance reserves	15,820	—	—	15,820
Total current liabilities	928,780	217,081	(171,231)	974,630
Long-term debt, net of current portion	1,722,940	5,323	—	1,728,263
Noncurrent portion of operating lease liabilities	773,254	9,924	—	783,178
Fair value of interest rate exchange agreements	45,019	—	—	45,019
Noncurrent portion of medical malpractice self-insurance reserves	65,816	—	—	65,816
Noncurrent portion of deferred revenue	1,547	13	—	1,560
Other noncurrent liabilities	8,624	232	—	8,856
Total liabilities	<u>3,545,980</u>	<u>232,573</u>	<u>(171,231)</u>	<u>3,607,322</u>
Net assets:				
Net assets without donor restrictions controlled by Vanderbilt University Medical Center	1,629,830	13,238	(12,000)	1,631,068
Net assets without donor restrictions related to noncontrolling interests	—	20,768	—	20,768
Total net assets without donor restrictions	1,629,830	34,006	(12,000)	1,651,836
Net assets with donor restrictions	268,432	—	—	268,432
Total net assets	<u>1,898,262</u>	<u>34,006</u>	<u>(12,000)</u>	<u>1,920,268</u>
Total liabilities and net assets	<u>\$ 5,444,242</u>	<u>\$ 266,579</u>	<u>\$ (183,231)</u>	<u>\$ 5,527,590</u>

The accompanying notes are an integral part of these consolidating financial statements.

Vanderbilt University Medical Center
Consolidating Balance Sheet
June 30, 2021

(\$ in thousands)	Obligated Group	Nonobligated Entity	Eliminations	Consolidated
Assets				
Current assets:				
Cash and cash equivalents	\$ 737,347	\$ 99,965	\$ —	\$ 837,312
Intercompany receivable	174,781	—	(174,781)	—
Current investments	215,484	—	—	215,484
Patient accounts receivable	530,712	23,162	—	553,874
Grants and contracts receivable	77,365	—	—	77,365
Inventories	137,279	3,002	—	140,281
Other current assets	99,962	18,297	—	118,259
Total current assets	1,972,930	144,426	(174,781)	1,942,575
Restricted cash	26,404	1,000	—	27,404
Noncurrent investments	791,389	—	(12,000)	779,389
Noncurrent investments limited as to use	127,414	—	—	127,414
Property, plant, and equipment, net	1,608,313	22,012	—	1,630,325
Operating lease assets	823,092	16,758	—	839,850
Other noncurrent assets	42,348	54,003	—	96,351
Total assets	<u>\$ 5,391,890</u>	<u>\$ 238,199</u>	<u>\$ (186,781)</u>	<u>\$ 5,443,308</u>
Liabilities and Net Assets				
Current liabilities:				
Current portion of long-term debt	\$ 13,906	\$ 798	\$ —	\$ 14,704
Intercompany payable	—	174,781	(174,781)	—
Short-term borrowings	300,000	—	—	300,000
Accounts payable and other accrued expenses	335,424	20,747	—	356,171
Medicare accelerated payments	187,370	2,057	—	189,427
Estimated liabilities under third-party programs	37,669	—	—	37,669
Accrued compensation and benefits	309,306	7,225	—	316,531
Current portion of operating lease liabilities	63,115	4,228	—	67,343
Current portion of deferred revenue	3,182	1,058	—	4,240
Current portion of medical malpractice self-insurance reserves	15,820	—	—	15,820
Total current liabilities	1,265,792	210,894	(174,781)	1,301,905
Long-term debt, net of current portion	1,430,398	1,752	—	1,432,150
Noncurrent portion of operating lease liabilities	782,199	13,131	—	795,330
Fair value of interest rate exchange agreements	76,864	—	—	76,864
Noncurrent portion of medical malpractice self-insurance reserves	56,770	—	—	56,770
Noncurrent portion of deferred revenue	2,335	588	—	2,923
Other noncurrent liabilities	46,122	864	—	46,986
Total liabilities	3,660,480	227,229	(174,781)	3,712,928
Net assets:				
Net assets without donor restrictions controlled by Vanderbilt University Medical Center	1,506,852	2,631	(12,000)	1,497,483
Net assets without donor restrictions related to noncontrolling interests	—	8,339	—	8,339
Total net assets without donor restrictions	1,506,852	10,970	(12,000)	1,505,822
Net assets with donor restrictions	224,558	—	—	224,558
Total net assets	1,731,410	10,970	(12,000)	1,730,380
Total liabilities and net assets	<u>\$ 5,391,890</u>	<u>\$ 238,199</u>	<u>\$ (186,781)</u>	<u>\$ 5,443,308</u>

The accompanying notes are an integral part of these consolidating financial statements.

Vanderbilt University Medical Center
Consolidating Statement of Operations
Year Ended June 30, 2022

(\$ in thousands)	Obligated Group	Nonobligated Entity	Eliminations	Consolidated
Operating revenues				
Patient service revenue	\$ 5,092,541	\$ 263,732	\$ —	\$ 5,356,273
Academic and research revenue	693,847	12,012	—	705,859
Other operating revenue	243,992	58,901	(24,157)	278,736
Total operating revenues	<u>6,030,380</u>	<u>334,645</u>	<u>(24,157)</u>	<u>6,340,868</u>
Operating expenses				
Salaries, wages, and benefits	3,134,589	169,744	—	3,304,333
Supplies and drugs	1,378,740	49,207	(1,008)	1,426,939
Facilities and equipment	285,095	21,349	(66)	306,378
Services and other	847,609	94,879	(23,083)	919,405
Depreciation and amortization	165,612	7,387	—	172,999
Interest	59,231	699	—	59,930
Total operating expenses	<u>5,870,876</u>	<u>343,265</u>	<u>(24,157)</u>	<u>6,189,984</u>
Income from operations	<u>159,504</u>	<u>(8,620)</u>	<u>—</u>	<u>150,884</u>
Nonoperating revenues and expenses				
Loss from investments	(71,057)	—	—	(71,057)
Gift income	21,477	—	—	21,477
(Losses) earnings of unconsolidated organizations	(1,417)	10,809	—	9,392
Unrealized gain on interest rate exchange agreements, net of cash settlements	25,841	—	—	25,841
Other nonoperating (losses) gains	(8,713)	14,670	—	5,957
Total nonoperating revenues and expenses	<u>(33,869)</u>	<u>25,479</u>	<u>—</u>	<u>(8,390)</u>
Excess of revenues over expenses	125,635	16,859	—	142,494
Excess of revenues over expenses attributable to noncontrolling interests	—	(8,886)	—	(8,886)
Excess of revenues over expenses attributable to VUMC	<u>\$ 125,635</u>	<u>\$ 7,973</u>	<u>\$ —</u>	<u>\$ 133,608</u>

The accompanying notes are an integral part of these consolidating financial statements.

Vanderbilt University Medical Center
Consolidating Statement of Operations
Year Ended June 30, 2021

(\$ in thousands)	Obligated Group	Nonobligated Entity	Eliminations	Consolidated
Operating revenues				
Patient service revenue	\$ 4,545,568	\$ 146,246	\$ —	\$ 4,691,814
Academic and research revenue	613,820	791	—	614,611
Other operating revenue	198,001	49,401	(19,198)	228,204
Total operating revenues	<u>5,357,389</u>	<u>196,438</u>	<u>(19,198)</u>	<u>5,534,629</u>
Operating expenses				
Salaries, wages, and benefits	2,736,936	99,608	—	2,836,544
Supplies and drugs	1,195,859	21,117	(773)	1,216,203
Facilities and equipment	283,721	13,149	(122)	296,748
Services and other	749,557	64,033	(18,303)	795,287
Depreciation and amortization	147,977	3,477	—	151,454
Interest	60,400	130	—	60,530
Total operating expenses	<u>5,174,450</u>	<u>201,514</u>	<u>(19,198)</u>	<u>5,356,766</u>
Income from operations	<u>182,939</u>	<u>(5,076)</u>	<u>—</u>	<u>177,863</u>
Nonoperating revenues and expenses				
Income from investments	68,201	—	—	68,201
Gift income	19,104	—	—	19,104
(Losses) earnings of unconsolidated organizations	(683)	8,783	—	8,100
Unrealized gain on interest rate exchange agreements, net of cash settlements	<u>17,372</u>	<u>—</u>	<u>—</u>	<u>17,372</u>
Total nonoperating revenues and expenses	<u>103,994</u>	<u>8,783</u>	<u>—</u>	<u>112,777</u>
Excess of revenues over expenses	286,933	3,707	—	290,640
Excess of revenues over expenses attributable to noncontrolling interests	<u>—</u>	<u>(6,295)</u>	<u>—</u>	<u>(6,295)</u>
Excess of revenues over expenses attributable to VUMC	<u>\$ 286,933</u>	<u>\$ (2,588)</u>	<u>\$ —</u>	<u>\$ 284,345</u>

The accompanying notes are an integral part of these consolidating financial statements.

Vanderbilt University Medical Center
Note to Supplementary Information
June 30, 2022 and 2021

1. Basis of Presentation

As discussed in Note 11 Long-Term Debt, each of the bonds and notes comprising the Series Debt represent separate obligations under an MTI structure. All debt issued under the MTI are general obligations of the obligated group, which, for purposes of the preceding consolidating financial statements comprises VUMC and its affiliates, as described in Note 1 Description of Organization, except for VHS, HPS, NashBio, VTHH, VBCH, and VMH, which are nonobligated entities.

The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position and the results of operations of the individual companies.

The accompanying notes are an integral part of these consolidating financial statements.